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  Introduction 




Memory is an integral part of us. It shapes our understanding and connects us with the world. 
Without memory, our life will be meaningless. Various brain regions, including the 
hippocampus, cortex, cerebellum, striatum, the amygdala can take part in the acquisition, 
storage, and retrieval of memory. Memory can be broadly classified into two types: a) implicit 
(non-declarative) memory for skill and motor functions that require reflexes and b) explicit 
(declarative) memory for facts, people, and events.  
 
Little was known about how implicit and explicit memory are formed, and stored until the 
1960´s. Later, many of the current understandings of memory in molecular and cellular level 
evolved from studies investigating Aplysia, a simple invertebrate model. Aplysia has only 
20,000 nerve cells compared to a trillion in the mammalian brain1. Molecular mechanisms of 




Aplysia displays a defensive gill-withdrawal reflex after light touch to the siphon. By applying 
a strong stimulus to its tail (tail shock), the withdrawal reflex of both gill and siphon can be 
enhanced, a process that is known as sensitization of the gill-withdrawal reflex (Fig T1).  
 
 
Fig T1. A simple learned behavior in Aplysia.  
Application of mild touch to Aplysia´s siphon 
leads to withdrawal its gill. This reflex is further 
strengthened after applying a tail shock. Figure 




During sensitization, the stimulus on the modulatory neurons from tails leads to release 
serotonin onto sensory neuron of the siphon2,3. Serotonin, by binding to a transmembrane 
receptor on pre-synaptic compartment activates Adelylyl cylase, which converts ATP to cAMP4 
(Fig T2). cAMP activates protein kinase A (PKA) at pre-synaptic terminals leading to enhanced 
availability and release of glutamate, a neurotransmitter, into synaptic cleft5,6. If the actual 
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stimulus (tail shock) is preceded by conditioned stimulus (stimulation of siphon)7, the synaptic 
strength is further increased and thus there will be a stronger gill-withdrawal reflex. This short 
time synaptic strength involves covalent modifications of preexisting proteins but no new 
protein synthesis1,8-10.  
 
Repeated, spaced stimuli produce synaptic strength that can stay longer than that from single 
stimuli, and thereby forms long term implicit memory. The difference between long-term and 
short-term memory is that long-term memory requires new protein synthesis, and it requires 
post-synaptic depolarization11. During long term memory formation, serotonin-induced cAMP 
and PKA persists. Protein kinase A, in turn, activates mitogen-activated protein kinase (MAPK) 
and both move to the nucleus and then phosphorylates transcription factor CREB-1 and thereby, 
activates it12. CREB-1 can initiate gene expression changes in two phases: a) the first wave of 
immediate-early genes expression and b) the second wave of gene expression by inducing 
enhancer-binding transcription factor, C/EBP13,14. Newly synthesized mRNAs are then 
delivered to specific synapses, whose stimulation initially triggered CREB-1 dependent gene 
expression. This phenomenon is termed as “synaptic tagging”, and that is newly synthesized 
molecules will be delivered throughout the cell but will be only used in active synapses15,16. 
Transported mRNAs are translated into protein locally at the synapse17. Increased activity of 
PKA and local protein synthesis mark active synapses16. Of note, local protein synthesis is 
essential for maintaining long term memory as well. Subsequent studies revealed that the 
function of CREB-2 could inhibit the function of CREB-1, a memory suppressor gene, and 
through microRNAs (e.g., miR-124)18-20. Thus, memory formation is under tight regulation and 
memory suppressor genes providing a checkpoint for memory storage. However, increased 
serotonin levels could alleviate these suppressions. 
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Fig T2. Signaling cascade that underlies early and late implicit memory in Aplysia.  
a) Stimulus dependent pre-synaptic activation leads to increased intracellular Ca2+ concentration. Ca2+, in turn, 
activates adenlyl cyclase enzyme produce cAMP that triggers PKA mediated vesicle movement and 
neurotransmitter release into synaptic cleft. (b) In the presence of post-synaptic depolarization, along with pre-
synaptic changes, post-synapic NMDA and PLC receptors become activated. As a result, increased Ca2+ influx 
through NMDA receptor and Ca2+ release from cellular reservoirs increase Ca2+ within post-synaptic compartment. 
Ca2+, in turn, initiates several cellular signaling processes including recruitment of AMPA receptors on the post-
synaptic membrane. Moreover, glutamate released from post-synaptic compartment can act as retrograde signaling 
molecule to allow persistent cellular changes in pre-synaptic compartment. Figure modified from Roberts and 
Glanzman11. 
 
Long term facilitation of implicit memory could be destabilized by protein degradation and 
later could be re-stabilized by protein synthesis at the same synapse21. Glutamate induced post-
synaptic activation of NMDA receptors and Phospholipase C (PLC) during long term implicit 
memory leads to increased intracellular Ca2+, that in turn, recruits AMPA receptors on the post-
synaptic membrane via PKC (Fig T2) and release of glutamate as retrograde signaling molecule 
to trigger persistent pre-synaptic changes11. Similar mechanisms of implicit memory are found 
in the mammalian brain by classical fear conditioning experiments in animals. 
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Unlike implicit memory, explicit memory in mammalian brain involves hippocampal-
dependent tasks. Like implicit memory, explicit memory has a short-term phase (lasts only 1 to 
3 hours) that is independent of protein synthesis and a long-term phase that requires protein 
synthesis. There are two types of brain cells, a) place cells in the hippocampus and b) grid cells 
in the entorhinal cortex, help in making navigational maps of the environment, and encode 
spatial information in the brain. Terje Lomo and Tim bliss first discovered activity dependent 
plasticity in hippocampus22, now known as long term potentiation (LTP). long-term 
potentiation (LTP) plays a significant role in memory in the mammalian brain. The first direct 
evidence regarding the role of LTP in hippocampal memory came through pharmacological 
interventions. Morris et al. used NMDA antagonist to block post-synaptic NMDA receptors in 
the rat´s brain and tested their spatial memory in the water maze23. Animals with inhibition of 
NMDA receptors displayed spatial navigation deficits. Subsequent studies knocked out NMDA 
receptors specifically at various brain regions that led to different responses in mice. For 
example, transgenic mice with a knockdown at CA1 displayed spatial learning and memory 
deficits, whereas with a knockdown at CA3 and DG regions mice exhibited deficits in pattern 
completion, and pattern discrimination, respectively24-26. 
 
NMDA receptor resides only on the post-synaptic terminal of a neuron. To be active, the post-
synaptic terminal has to be depolarized and glutamate has to be released from the opposed pre-
synaptic part. Thus, the activation of NMDA receptor marks active synapses. Once activated, 
NMDA receptors can increase Ca2+ influx, and initiate several molecular signaling pathways 
leading to the induction of LTP. There are two phases of LTP. The early phase involves 
activation of cAMP, leading to the recruitment of new AMPA type glutamate receptors and 
thus accompany strengthened response. The late phase, by contrast, requires both gene 
expression and translation16. In terms of molecular mechanisms, late-phase LTP is similar to 
long term implicit memory in Aplysia. Therefore, it involves PKA, MAPK signaling pathways, 
CREB-1 mediated gene transcription, distribution of newly synthesized proteins according to 
synaptic tagging hypothesis. Moreover, the late phase is associated with NMDA dependent 
dendritic spines enlargement and structural changes in the synapse. However, LTP induction 
can also be NMDA independent. For example, in CA3 neurons, LTP at mossy fiber synapse is 
solely dependent on the pre-synaptic neurotransmitter, and thus, post-synaptic NMDA 
independent27,28. Moreover, induction of LTP can vary across different brain regions and also 
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within the same region with different patterns of stimuli. For instance, 100 Hz stimulation in 
the hippocampus induces LTP that is dependent on NMDA receptor activation, but 200 Hz 
stimulation-induced LTP requires voltage-gated Ca2+ channels16.  
 
Prolonged synaptic stimulation at low frequency can lead to NMDA dependent long-term 
depression (LTD). Moreover, pre-synaptic activity produced shorty after post-synaptic action 
potentials also leads to LTD. Consequently, Ca2+ dependent phosphatases are recruited, leading 
to a reduction in AMPA receptors at post-synaptic compartment29. In a recent study30, Camin 
Dean and her colleagues showed that Synaptotagmin 3 (Syt3) could mediate AMPA receptor 
endocytosis, and therefore, Syt3 expression might underlie forgetting. Indeed, Syt3 knockout 
mice could not forget a learned task in the water maze.  
 
 
Although forgetting is as essential as the formation of memory in physiological condition, a 
decline in both during dementia leads to disturbances in daily performances. According to the 
World Health Organization (WHO), worldwide, around 50 million people have dementia. 
Major risk factors of dementia include cardiovascular factors and aging. 
 
Heart failure and memory 
 
Multiple feedback mechanisms connect the heart and brain, and these two vital organs share 
several pathophysiological mechanisms. Both organs are affected by common risk factors 
including impaired metabolism, age, gender, and educational status31-33. Therefore, heart and 
brain diseases often co-exist in patients34,35.  
 
Cardiac dysfunctions affect blood perfusion to the brain. At high blood pressure, the brain 
vascular system can maintain normal perfusion. However, at low blood pressure, regional 
hypoperfusion can occur. Cardiac failure leads to chronic hypoperfusion in the brain. Regional 
perfusion in brain is monitored by “neuro-vascular unit” that is composed of different cell types, 
including neurons, glia, and pericytes36. Therefore, regional hypoperfusion in chronic heart 
failure may accompany changes in these cell types. Structural and metabolic abnormalities 
along with a functional decline in multiple brain regions have been observed in patients with 
heart failure37-41. For example, reduced blood flow in bilateral areas of the prefrontal cortex, 
hippocampus, and thalamus have been reported in patients with heart failure. Patients with heart 
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failure have been diagnosed with structural changes in different brain regions, including grey 
and white matter38. Consistently, reduced cortical thickness and extensive tissue loss in 
hippocampus38 (Fig T3) and cortex40 are observed in patients with heart failure.  
 
Fig T3. Regional hippocampal damage in 
heart failure patients.  
Figure is highlighting the magnitude of 
hippocampal atrophy in heart failure 
patients. The right hippocampus (a-f) 
demonstrates more atrophy than the left (g-
h). Color is representing the severity of 
atrophy in HF patients compared to controls. 
Red and orange color represent more 
severity of local tissue volume loss. Figure 






In line with structural changes in the brain, recent epidemiological studies reported a cognitive 
decline in heart failure patients42-46. Most of the patients are diagnosed with mild cognitive 
impairment, whereas some suffer from moderate to severe dementia.  Patients with failing heart 
experience deficits in multiple cognitive domains, including executive function, attention, 
processing speed, visual spatial functions, leaning, and working memory46. Treatment for 
dementia in heart failure patients has been empirical44. Targeted and knowledge-based effective 
therapeutic invention is urgently required to improve cognition in heart failure patients44.  
 
Aging and memory 
 
Although aging is a significant risk factor for dementia 47-50, it is difficult to separate the cognitively 
healthy aging from that of the pathological condition. Based on several cross-sectional and 
longitudinal data51, it is now evident that some aspect of cognition like processing speed starts 
declining at the early 30s of healthy individuals. Other cognitive domains, including working memory, 
episodic memory decline after 55 years of age (Fig T4).  
 
The effect of aging on memory is highly reproducible in animals. Age-associated hippocampal-
dependent memory deficits and reduced synaptic plasticity have been reported in several animal 
studies 53-55. 
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Fig T4. Timeline for age-related changes in cognition.  
(a) Cross-sectional data are showing a decline in all cognitive domains after 55 years except numeric and verbal ability. 
(b) Longitudinal data illustrating a decline in all domains after 55 years. Figure adapted from Hedden T and Gabrieli, J.D52  
 
 
At the cellular level, aging alters several biological processes and pathways, including insulin 
signaling, TOR signaling, mitochondrial function, autophagy, and stress responses. While, insulin and 
IGF-1 can promote learning and memory in humans and animal models56, its reduction along with 
aging has been conserved in worms, flies, and mammals57. Mitochondrial function and TOR signaling 
pathways also play a critical role in physiological aging and maintaining cognition58-62. Deficits in 
mitochondrial function causes decreased lifespan. Decreased signaling of TOR pathways leads to 
increased autophagy and decreased protein translation. Altered autophagy and TOR signaling 
pathways have been linked to Alzheimer´s disease63, and memory64. Genome-wide transcriptome 
analysis revealed that genes involved in stress, mitochondrial energy metabolism, neural 
plasticity/synaptic function, inhibitory interneuron function, ubiquitin-proteasome pathway, immune 




Alzheimer´s disease (AD) is an age-related neurodegenerative disease and the most common form of 
dementia with increasing prevalence67. At the structural level, patients display distinct brain atrophy. 
Microscopic changes in AD patients include extracellular deposition of Amyloid-ß (Aβ) plaques and 
intracellular neurofibrillary tangles (NFTs) from misfolded Tau (Fig T5), a microtubule-associated 
protein. AD is associated with severe neuronal loss and increased gliosis that accompany irreversible 
memory decline, disorientation, and confusion in patients68. While deposition of Aβ plaques in AD 
patients starts in prefrontal brain regions followed by spreading over the cortex, the NFTs show a 
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highly specific spreading pattern69. In general, deposition of the tangles happens starts at the trans-
entorhinal cortex (Braak stage I). At stage II it spreads to the entorhinal cortex and Ammon´s horn in 
the hippocampus. At stage III, the rest of the hippocampal regions, amygdala, and the anterodorsal 
thalamic nuclei are affected. Finally, tau tangles spreading over the cerebral cortex leading to atrophy70 




Fig T5. Pathological hallmarks of Alzheimer´s disease.  
Brain atrophy in Alzheimer´s disease (AD) is associated with the loss of brain cells. Deposition of extracellular amyloid-
ß plaques and intracellular neurofibrillary tangles is linked to loss of neurites, synapse, and increased gliosis. Increased 
inflammatory response via microglia is also observed in AD pathology. Figure adapted from Congdon EE et al.71 
 
Evidence shows that the progression of AD is slow, and changes in brain function take place years 
before the onset of dementia72,73. At the pre-clinical phase, early neuronal and metabolic changes 
happen in the hippocampus and entorhinal cortex, the regions that also harbor place and grid cells, 
essential for spatial navigation. Increased neuronal loss leading to volumetric decline contributes to 
disturbances in both episodic and semantic memory at mild cognitive impairment (Fig T6). In the 
early AD phase, neuronal loss continues in various brain regions, including the prefrontal cortex, the 
brain region that is involved in executive functioning and memory retrieval.  
 
Clinical trials for all the drugs tested so far for AD have been failed74. Aducanumab, from Biogen and 
Eisai, is the last addition to this list as the biotech company announced in 2019 that it would 
discontinue phase 3 trials. Failure to accurately detect AD pathology at an early stage is one of the 
significant reasons why drugs have not been successful. Early accurate detection of AD is crucial and 
might allow applying early pharmacological interventions to stop or delay disease progression. We 
will need useful biomarkers to diagnose incipient patients at the pre-clinical stage. 
Healthy 
AD 
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Fig T6. Progressive changes in AD brain.  
a) Early changes in the hippocampus and the entorhinal cortex may affect spatial navigation at pre-clinical AD. 
b) increased neuronal loss accompany volumetric loss in the medial temporal and parietal lobes of mild cognitively 
impaired AD patients. 
c) rest of the medial temporal lobe, and frontal lobe are affected at an early AD. Spatial navigation is severely affected at 
an early AD. Figure adapted from Coughlan et al.75 
 
Histone modification and memory 
 
A long stretch of DNA is packaged into the microscopic nucleus in the form of chromatin. 147 
base pairs long DNA is wrapped around a histone octamer to form a nucleosome, the core unit 
of chromatin76. Subsequently, chromatin adopts a high order organization to position itself 
within the nucleus. All Histones H2A, H2B, H3, H4 in nucleosomes can be post-translationally 
modified, mostly at different amino acid residues on their tails. Various modification marks on 
histones determine whether chromatin will be transcriptionally active (euchromatin) or inactive 
(heterochromatin). Active chromatin will adopt a relaxed and open state allowing non-histone 
transcription factors and enzymes to interact with DNA. Interactions between different histone 
modifications and DNA can determine the fate of a gene. These histone-DNA interactions can 
happen at the promoter, gene-body, and enhancer of a gene. A transcriptionally active gene 
often has H3K4me3, H3K4me2, and H3K9ac modifications at its promoter, whereas 
H3K27me3, H3K9me3 will mark an inactive gene promoter77. Some genes are only temporally 
expressed, therefore are termed as poised. These genes have both an active (H3K4me3) and an 
inhibitory mark (H3K27me3) at their promoters77. Histone modification at gene body (e.g., 
H3K36me3) can affect the splicing of a given gene78.  
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Different histone mark readers can recognize the existing histone modification mark; writers 
can place marks and erasers can remove histone marks to shape distinct expression patterns76. 
For example, Kmt2a is a methyltransferase that will add methylation on Histone 3 lysine 4 
residue leading to gene activation, whereas HDAC is a histone deacetylase, that can erase acetyl 
group from Histone 3 lysing 9 residue and thus inactivates gene expression. Inhibitors of HDAC 
[e.g., Vorinostat (SAHA)] can inhibit the function of the HDAC and alter gene expression79.  
 
Histone modifications can change upon different environmental stimuli and play a key role in 
memory formation. In one of the first experiments to link histone modification with memory, 
Fischer et al. investigated the effects of environmental enrichment on histone modifications80. 
Authors showed that environmental enrichment increased histone acetylation in mice brain and 
could restore the memory of the memory-impaired mice. By using HDAC inhibitors (e.g., 
sodium butyrate and TSA), the cognitive benefits from increased acetylation could be 
reproduced80. Besides acetylation, changes in histone methylation have been linked to memory. 
Gupta et al. reported that increased H3K4me3 at the promoter of memory-related genes happen 
after 1h of associative learning81. Moreover, recent studies revealing that modulation of 
different histone-modifying enzymes (e.g., methyl and acetyl transferases) can affect memory 
as well 82-84.  
 
microRNAs and memory 
 
microRNAs are ∼19-22 base long small nuclear RNAs that regulate target gene expression at the post-
transcriptional level in healthy and disease conditions 85,86. Their key roles include cell differentiation 
and signaling, development, and pathogenesis of many neurological disorders 87,88. The biogenesis of 
microRNA has been conserved in all mammals 89. Both RNA polymerase II (Pol II) and III (Pol III) 
can synthesize primary microRNA transcript (pri-microRNA) in the nucleus (Fig T7). Once pri-
microRNA is synthesized, it is then cleaved by the Drosha–DGCR8 (Pasha) microprocessor complex 
and produces precursor microRNA (pre-microRNA). Subsequently, pre-microRNA is exported from 
the nucleus to the cytoplasm by Exportin-5–Ran-GTP (Fig T7). In the cytoplasm, an enzyme named 
Dicer cleaves the pre-microRNA hairpin to produce double-stranded mature microRNA. One of these 
strands remains functional as it is guided toward its target mRNA by Argonaute (Ago2) proteins and 
by binding to its 3’ UTR region can silence target mRNA expression. Depending on its full or partial 
complementary sequences, silencing could be achieved through one of the processes from mRNA 
cleavage, translational repression, or de-adenylation (Fig T7). The other strand of the mature 
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microRNA is called the passenger strand, and later degraded. Of note, one microRNA can target 
multiple mRNAs, and in turn, one mRNA can be targeted by more than one microRNA, giving rise 














Fig T7. microRNA biogenesis. 
Precursor microRNAs (pre-microRNAs) are transcribed in the nucleus. Pre-microRNAs are transported to cytoplasm via 
a transporter called Exportin 5. Dicer removes the hairpin from the pre-microRNA to produce double-stranded mature-
microRNAs. One of the strands is guided towards the site of action by the RISC complex. The other strand is called the 
passenger strand, and it is degraded. At the target site, microRNAs can repress the target genes expression by target 
mRNAs cleavage, translation repression, and target mRNA de-adenylation. Notably, one microRNA can regulate multiple 
target genes. Figure adapted from Winter J et al.90 
 
Rajasethupathy et al. showed that one microRNA, miR-124 could inhibit the function of CREB-1 
transcription factor leading to reduced synaptic plasticity and memory in Aplysia 91. Later, 
microRNA-mediated regulation of learning and memory was also reported in Drosophila 92. 
Subsequently, the microRNA processing enzyme, Dicer, was linked to learning and memory 93. Cell 
type-specific knockout of Dicer enhanced synaptic plasticity and memory in a variety of learning 
tasks, including spatial learning in the Morris water maze, and contextual and trace fear conditioning. 
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These effects were accompanied by decreased expression of several microRNAs, including miR-125b 
and miR-132, which were previously shown to be expressed locally and regulate dendritic spine 
formation94. A recent study reported that miR-34c might play a role in memory impairment95. Authors 
have observed an increased level of miR-34c in the hippocampus of 24 months old mice, a model for 
age-associated memory impairment. This increased level of the miR-34c was correlated with impaired 
memory function in the water maze test, and functionally could repress the Sirt1 protein expression. 
Another study showed that increased Sirt1 enhances dendritic spine density and synaptic plasticity in 
the hippocampus through the down-regulation of miR-134 96. Thus, several microRNAs can crosstalk 
with the same mRNA or different mRNAs in a gene regulatory network and can play a key role in 
fine-tuning gene expression patterns in response to learning and memory.  
 
microRNAs as biomarker and therapy 
 
microRNAs have the potentials to be biomarkers for several reasons. For example, they are highly 
conserved among species, extremely stable in different experimental conditions, and key gene 
regulatory elements in the biological system. Moreover, the systemic circulation of microRNAs 
enables them to take part in cell-to-cell communication and signaling in normal biological processes97 
as hormone does98. Additionally, microRNA levels from biological fluids can be quantified easily in 
limited experimental settings. In line with this, recent studies have shown that subsets of microRNAs 
may have clinical relevance as biomarkers to diagnose a particular stage, and progression of the 
disease99-101. Measuring the microRNAome in the blood is discussed as a promising strategy to 
develop biomarkers for brain102 and other human diseases 103. Despite its high promise, effective 
microRNA-based biomarker to diagnose incipient dementia is still missing.  
 
A number of studies revealed therapeutic potentials of microRNAs104-107. Recent FDA approval of 
first small RNA based (application number: 210922) in 2018 is one step forward towards microRNA-
based therapeutics. More biotech companies (e.g., Miragen, Regulus Therapeutics, Synlogic) are now 
investing in the development of microRNA-related drugs. Several drugs related to different 
microRNAs including MRX34 (miR-34), MRG 110 (miR-92), MesomiR-1 (miR-16), Miravirsen 
(miR-122), MRG-201 (miR-29), RG-012 (miR-21), MRG-106 (miR-155) are already in clinical 
trials108. Although the drugs mentioned above are being tested in mostly cancer treatment, microRNA-
based drug to improve cognition in dementia remain underexplored. 
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Summary 
 
Dementia is the most significant health challenge in modern times, currently affecting over 50 million 
people worldwide. The number of people afflicted with this disorder is on the rise and expected to 
double by 2025. Causative and symptomatic treatments of this disease have been so far unsuccessful. 
This is partly due to the fact that patients are only diagnosed with dementia at an advanced stage, 
when a massive neuronal loss has already manifested. There is substantial evidence memory 
impairment is preceded by molecular changes that happen years before the onset of cognitive decline. 
Therefore, there is an urgent need for biomarkers to diagnose early changes in the brain, which would 
allow clinicians to intervene therapeutically at an earlier phase of the disease. Moreover, it is equally 
important to study the underlying mechanisms of risk factors that might precipitate these early changes 
in the brain. Management of those risk factors may significantly reduce the progression of dementia 
or even prevent the onset of the disease. 
 
Therefore, in this cumulative thesis, I first tested the hypothesis that microRNAs in blood could be 
potential early diagnostic biomarkers for dementia. By using human cross-sectional and mouse 
longitudinal data, coupled with advanced multi-step systems biology approach, I report a blood-based 
“microRNA signature” that can inform about early cognitive decline in healthy and pathological 
conditions. Intriguingly, by manipulating the level of one of the signature microRNAs, I could 
improve memory in cognitively impaired mice. These data suggest that the “microRNA signature” 
that I report can not only be used as a diagnostic marker but also as a therapy to manage cognitive 
deficits in early dementia.  
 
In addition, I investigated how cardiac failure, a risk factor of dementia, could affect brain functions 
at the molecular level. By using transgenic mice with failing hearts, I report down-regulation of 
memory-related genes in the hippocampus leads to cognitive deficits in transgenic mice. Analyses of 
genome-wide distribution of H3K4me3 reveal that reduced levels of H3K4me3 at the promoters of 
genes may underpin cognitive changes. Consistently, through oral administration of SAHA, an 
inhibitor of HDAC, I delineate that the observed cognitive deficits can be rescued. At the molecular 
level, SAHA could partially restore both microRNAome and RNAome, highlighting its potential as a 
therapeutic intervention to ameliorate cognitive deficits following heart failure. 
 
Both of these studies provide key insight to molecular underpinnings and therapeutic interventions of 
early dementia. While epigenetic biomarker based on microRNAs could be useful to stratify 
individuals at risk of developing dementia, epigenetic drugs could be suitable strategy to restore 
memory and attenuate the future risk of dementia. 
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Abstract  
Deregulation of cognitive function is a key pathological hallmark of various 
neuropsychiatric and neurodegenerative diseases. Thus, there is an urgent need for 
minimally invasive biomarkers that could inform about future risk of developing cognitive 
defects. Here, we established an experimental approach suitable for the identification of 
circulating microRNAs that inform about cognitive decline at the preclinical phase. We 
combined healthy human cross-sectional data with mouse longitudinal data and several 
other in house and published datasets through an unbiased feed-forward feed-backward 
screening approach. We report a robust “microRNA signature” of three microRNAs that 
inform about early cognitive deficits. We could further show that through manipulation of 
one of these signatures, microRNA-181a-5p, early cognitive deficits could be ameliorated 
in mice. We suggest that our “microRNA signature” would be very informative for the 
early diagnosis of dementia. While further clinical trials will be necessary to test both 
signature and inhibitor in a large human cohort, our data provide strong evidence about 
potentials of the signature as an early diagnostic marker and microRNA-181a-5p inhibitor 
as an effective therapeutic intervention in early dementia.   
 
Key words: microRNA, brain plasticity, neurodegeneration, Alzheimer’s disease, 
biomarker 
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Introduction 
Impaired cognitive function is a key pathological hallmark of various neuropsychiatric and 
neurodegenerative diseases, and in many instances, pathological changes in cognitive function 
increase slowly over time 1. Bonafide examples are age-associated neurodegenerative diseases 
such as Alzheimer’s disease (AD). As a result, AD patients are often only diagnosed at an 
advanced stage of pathology, which is considered to be a significant reason why causative 
treatments are so far ineffective 2,3 4 5 6. Therefore, there is a general need for a biomarker that 
could inform about cognitive function and help to monitor healthy individuals to detect patients 
at risk for developing cognitive diseases. Advances in this direction stem, for example, from 
innovative structural and functional brain imaging approaches 7 that are however not suitable 
for monitoring healthy individuals in the context of routine annual check-up screenings. 
Therefore, an inexpensive and minimal invasive molecular biomarker that would help to enrich 
individuals at risk who could then undergo more detailed, cost-intensive and time-consuming 
examinations are urgently needed. A recent line of research indicates that circulating small 
non-coding RNAs could serve as diagnostic biomarkers for various disorders 8, including brain 
diseases 9 10 11 12 10,13-16 17 18. The best-studied small non-coding RNAs are microRNAs that are 
19-22 nucleotide long RNA molecules regulating protein homeostasis via binding to a target 
mRNA thereby causing its degradation or inhibition of translation 19. MicroRNAs are 
particularly interesting as potential biomarkers since changes in the microRNAome are 
believed to reflect subtle changes in cellular homeostasis. Moreover, microRNAs are extremely 
stable in cell free environments, are resistant to thaw-freeze cycles 10 and have been implicated 
with learning and memory function and dementia 20 21 22 23 24. Besides, microRNA based 
therapies were able to improve cognitive function in rodents 25 26. In this study, we aim to 
identify circulating microRNAs that could inform about cognitive performance at the onset of 
cognitive decline. We base our approach on the integrative analysis of humans and 
corresponding rodent models. To this end, we identify microRNAs that correlate with the inter-
individual variability in cognitive performance in healthy humans. Our data indicate that these 
microRNAs control signaling pathways linked to the aging process. We, therefore, study blood 
microRNAome of aging mice longitudinally. Via an integrative analysis combining both 
mouse and human data, we identify “microRNA signature” consisting of three microRNAs. 
Our circulatory signature shows increased expression at the early onset of cognitive decline in 
both mice and humans. Similar expression changes are also observed in CSF, plasma, and 
blood from humans with mild cognitive impairment. We further show that inhibition of 
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microRNA-181a-5p, one of the members of the signature, provides cognitive benefits to mice. 
We suggest the analysis of the reported “microRNA signature” should be included in ongoing 
longitudinal clinical and population-based studies that measure cognitive function to evaluate 
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Results  
Asymptomatic changes in circulating microRNAs are linked to cognitive variability in 
young, healthy humans  
Our study aims to identify circulating microRNAs that could inform about cognitive 
function and have potentials as an early diagnostic marker for dementia. Since preclinical 
molecular changes in dementia develop decades earlier27,28, a comparison between healthy 
and demented subjects to identify markers would be a suboptimal approach. Therefore, we 
decided to take advantage of the fact that cognitive abilities vary in healthy individuals 29 
and asked whether circulating microRNAs could correlate with these variabilities. Thus, 
we recruited 132 healthy individuals (age 25.95 ± 5.1 years) that were subjected to a 
battery of eight different cognitive tests to determine their executive function, working 
memory and intelligence (Budde et al., 2018 in press; http://www.psycourse.de). Next, we 
collected blood samples from all participants at the time of memory testing (Fig 1A). As 
blood collection approach, we employed PAXgene based method as we found out that 
application of this method was easiest in clinical settings and microRNAome data obtained 
from this method are highly reproducible and comparable between mouse and human (Fig 
S1). Subsequently, isolated RNA from collected blood was subjected to small RNA 
sequencing.  After adjusting for gender effect on microRNA expression data, we carried 
out an unsupervised weighted co-expression clustering analysis and identified four co-
expression modules (Fig 1B). Next, we calculated for each individual a composite 
cognitive score (weighted cognitive performance) (see Methods for detail) and asked 
whether the weighted cognition could correlate with identified co-expressed modules. Our 
analysis revealed that among four modules, two (e.g., turquoise and blue) showed a 
negative correlation whereas one (brown) module showed a positive correlation with 
cognition (Fig 1B, Table S1). Relying on the human tissue atlas for microRNAs 30 we 
detected 17 circulating microRNAs (Table S2) from these three modules, which are also 
highly expressed in the brain and might, therefore, play a direct role in cognitive function 
(Fig 1C). 
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Fig 1. Analyzing circulating microRNAs in healthy human subjects.  
A. Outline of the experimental approach. Healthy subjects (74 male and 58 female) participated in an array of 
cognitive tests e.g., trail making tests (part A and B), digit symbol test, digit span forward and backward test, 
multiple-choice vocabulary and intelligence test (MWT-B) followed by the donation of blood for molecular 
analysis. RNA was isolated from frozen blood and subjected to small RNA sequencing. Samples were filtered 
based on sequencing data quality and presence of all of the aforementioned cognitive test scores, and thus, data 
from 132 individuals in total were used for downstream analysis. B. Weighted co-expression analysis of all 
expressed microRNAs found four cluster modules. A weighted cognitive score was enumerated from various 
cognitive domains based on factor analysis and later used to demonstrate a correlation between phenotype and 
microRNA expression.  Brown, blue, and turquoise cluster modules significantly (p-value <0.05) correlated with 
cognitive performance (n = 132, age 25.95 ± 5.1 years). Brown cluster displayed a positive correlation while both 
blue and turquoise clusters showed negative correlations with the cognitive score. C. Heat map showing the 
expression of microRNAs from brown, blue and turquoise clusters that displayed a significant association (p 
<0.05) with cognitive performance in various human organs. D. Target genes with strong experimental evidence 
for brain enriched microRNAs were retrieved from miRTarbase and used to perform gene ontology analysis. 
Featured significant (adjusted p-value < 0.05) biological processes include extracellular matrix organization, 
regulation of cell proliferation, apoptotic signaling processes, response to hypoxia, and aging. 
 
 
GO-term analysis of the confirmed mRNA targets of these microRNAs revealed that 
changes in their expression could affect aging (Fig 1D). These data suggest that changes 
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in circulating microRNAs at a young age may lead to subtle changes in aging-related 
processes and could thereby contribute to cognitive variabilities.  
Changes in circulating microRNAs correlate with age-associated memory decline in 
mice 
To investigate how aging could influence cognition and microRNA expression, we carried 
out our further experiments in mice. Age-associated memory decline is a well-established 
and highly reproducible phenotype in mice31, and both mice and humans share similarities 
in underlying molecular processes. To monitor longitudinal cognitive changes along with 
aging, we subjected mice to the water maze, a well-established test for spatial reference 
memory. Our decision was based on the fact that this test enables the sensitive and 
repeatable measure of several comparable cognitive domains in mice and in humans 32-34, 
a feature that is critical for longitudinal studies. Although old mice are known to show 
memory impairment (e.g., 20 months)35, a recent cross-sectional study revealed they could 
display earlier impairment. For example, compared with three months, mice display early 
cognitive deficits at 16 months, but they lack memory impairment at 12 months 36,37. 
 
Fig 2. Age-associated memory impairment in mice in a longitudinal experiment.  
A. Experimental design of the main experiment (n =10 each group). At 12 months of age, mice were 
subjected to the water-maze training protocol in order to habituate the animals to the procedure.  
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Subsequently, mice were subjected to water maze training followed by a probe test at 13.5, 15, and 16.5 
months of age. The platform position was altered during each training procedure. Blood was collected upon 
completion of each water maze procedure. A visual cued test was performed after the first and after the last 
blood collection when mice were 12 and 16.5 months of age, respectively. B. Left panel: Escape latency 
during water maze training among different age groups (Two-way ANOVA followed by Tukey´s multiple 
comparisons, training trials: p-value< 0.0001; age: p 0.0004).  On day one and two, there was a significant 
(p-value < 0.05) difference between mice at 13.5 vs. 16.5 months and 15 vs. 16.5 months of age. On the 5th 
day of training, there was a significant difference observed between 15 and 16.5 months of age. Right panel: 
Density plots for grouped data showing the position of mice in correspondence to the platform during the 
training days. C. Analysis of the different search strategies during the water training sessions. Note that 
especially at 16.5 months of age mice adapted hippocampal independent search strategies indicative of 
impaired cognitive function. D. The cumulative score for hippocampal-dependent strategies during water 
maze training was significantly impaired when comparing mice at 16.5 months of age to their performance 
at 15 or 13.5 months of age (Ordinary One-way ANOVA, Tukey`s multiple comparison test).  E-F. 
Performance during probe test. E. Average proximity (One-way ANOVA) and, F. Cumulative search 
strategy among groups (one-way ANOVA, Tukey`s multiple comparison test). *p<0.05, **p<0.01, 
***p<0.001. All error bars indicate mean ± SEM. 
 
 
Given that the average life span of mice is 24-26 months38,  we reasoned that analyzing 
spatial learning and memory in mice from early middle age (12 months) until late middle 
age (16.5 months) might allow us to investigate early cognitive transition. Therefore, a 
group of mice (n = 10) was subjected to spatial reference memory test at 12 months, and 
we repeated this every 1.5 month until mice became 16.5 months old, hence this group 
was termed as “learning group” (Fig 2A). We collected blood from mice at the 
aforementioned time points after the water maze test and importantly, repeated blood 
collection from orbital sinus did not affect their vision (Fig S2). Additionally, we collected 
blood from a group of aging mice that were not subjected to memory training. This group 
served as the control for effects due to water maze test, and it was named as “home-cage 
group” (Fig S3A). During spatial memory learning at evenly spaced time points, the 
location of the platform and the visual cues were randomly exchanged to examine newly 
formed spatial reference memories (Fig 2A). At 12 months of age, however, mice were 
allowed to habituate with water maze and did not perform the memory test. Therefore, we 
evaluated their performances in training and retrieval of reference memory at 13.5, 15, and 
16.5 months. Escape latency during the training procedure – a measure of spatial reference 
learning ability – was significantly impaired at 16.5-months compared with that from 13.5 
and 15 months (Fig 2B). Further sensitive analysis employing a modified version of the 
MUST-C algorithm 32 revealed various spatial strategies that mice employed during 
training (See methods for more details). This analysis showed us that between 15 and 16.5 
months of age mice adapted search strategies related to impaired cognitive ability (Fig 
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2C). Consistently, at 16.5 months, mice exhibited a reduction of hippocampal-dependent 
“direct”, “corrected”, “short chaining”, and “focused” search strategies (Fig 2C). In line 
with this, the cumulative cognitive score was significantly reduced at 16.5 months 
compared with that from 13.5 and 15 months of age (Fig 2D). Moreover, memory retrieval 
data revealed that average proximity was increased (indicates poor memory) (Fig 2E) 
whereas the mean strategy score (Fig 2F) were significantly reduced at 16.5 months of age 
compared with 13.5 months. Since all mice were able to find the platform rapidly in a 
visually cued test performed at 12 and 16.5 months of age (Fig S1), these data collectively 
show that at 16.5 months mice exhibit robust age-associated defects in both learning and 
memory of a spatial reference task. 
 
Next, we isolated RNA from collected blood and subjected this RNA to small RNA 
sequencing. We performed this experiment in both “learning” and “home-cage” group. 
We employed “home-cage” as a control group to exclude microRNAs that potentially 
deregulate in response to water maze training. The sequencing data obtained from both 
learning and home-cage groups was fit to a likelihood ratio test model and adjusted for 
hidden confounding factors. Thus, compared to expression data from 12 months, we found 
differentially expressed microRNAs at 13.5, 15, and 16.5 months. We detected 69 
deregulated microRNAs in the learning-group (Fig 3A), whereas 78 microRNAs were 
differentially expressed in the home-cage-group (Fig S3B, Table S3). Hierarchical and 
fuzzy clustering analysis revealed that the differentially expressed microRNAs detected in 
both groups fit into two main clusters: one cluster containing microRNAs that increased 
while the other representing microRNAs that decreased with advanced age (Fig 3B, Fig 
S3C). The specificity of these findings was further confirmed by the fact that many 
circulating microRNAs did not change during aging (Fig S3D). Next, we compared the 
differentially expressed microRNAs between “learning” and “home-cage” groups and 
identified 55 microRNAs that were similarly deregulated during aging (r = 0.99) in both 
groups (Fig S3E). These data indicate that the 55 microRNAs might reflect important 
homeostatic changes associated with the aging process and were named as “aging 
responsive” microRNAs (Table S4). Gene ontology analysis for the experimentally 
validated target genes of the 55 aging responsive microRNAs revealed that they might 
play a role in brain-specific processes, such as “modulation of synaptic transmission”, 
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Fig 3. Age-associated changes in the circulating microRNAome reveal pathways linked to cognitive 
function.  
A. Heat map showing microRNAs significantly deregulated during aging in the “learning group”. B. Fuzzy 
c-means clustering indicating the two main clusters of microRNAs differentially expressed in the learning 
group during aging. (C-D) Top biological processes and pathways identified based on experimentally 
validated target genes of the 55 microRNAs differentially expressed during aging. 
 
 
Integrative analysis of mouse and human data suggests a “microRNA signature” as a 
biomarker for early onset of cognitive dysfunctions 
To identify microRNAs indicative for cognitive performance in our longitudinal study, we 
employed an unbiased microRNA feature selection approach using Random Forest-based 
machine learning. First, we subjected the different water maze features to a principle 
component (PCA) analysis to identify the key factors explaining most of the variability in 
the data.  Most of the variability was explained by principal components 1 and 2 (PC1, 
PC2) (Fig S4). Next, to identify microRNAs informative about memory performance, we 
employed PC1 scores to subject the 55 aging-responsive blood microRNAs via two 
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independent methods for feature selection (Table S5), namely multivariate bootstrapping 
and multivariate leave one out cross-validation (Looc; see method for more details). Both 
approaches identified three microRNAs linked to memory performance consisting of 
microRNA-181a-5p, miR -146a-5p and microRNA-148a-3p and were termed as 
“microRNA signature”. microRNA members from “microRNA signature” were also part 
of the brown and blue co-expression modules linked to cognitive performance in healthy 
humans (Table S1, Fig 1), an observation that guided us to hypothesize that “microRNA 
signature” can potentially inform about cognitive status. Since these microRNAs are also 
part of “aging responsive” microRNAs (Table S4), their correlation with cognition could 
also be by chance, and therefore, they may not be informative. 
 
To investigate this in further detail, we analyzed the expression of “microRNA signature” 
in several human and mouse datasets related to aging and cognitive dysfunction. To this 
end, we calculated the co-expression of all three microRNAs based on singular value 
decomposition on expression data. Since, we previously observed early cognitive deficits 
in mice between 13.5 and 16.5 months (see Fig 2, Fig 4A), we tested whether co-
expression microRNAs could drive this cognitive transition. Of note, the cognitive deficit 
was highest at 16.5 months (see Fig 2, Fig 4A).  We found increased co-expression of 
“microRNA signature” in the blood of mice at both 15 and 16.5 months of age compared 
with 13.5 months (Fig 4B). Increased co-expression of the signature at both 15 (no 
cognitive deficits observed) and 16.5 (substantial cognitive deficits observed) months hint 
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of these three 
microRNAs were used 
to assay their co-
expression in several 
datasets. Before eigen-
expression calculation, 
age, sex, batch, and 
surrogate variables 
(determined by sva 
bioconductor package) 
were taken into 
consideration as per the 
data availability of the 
given experiment and fit 
into a mixed linear 
model to adjust 
expression data for 
these effects. A. Mice 
show cognitive 
impairment at 16.5 
months as represented 
by decreased (-
1)*average proximity 
during water maze test 
compared to 13.5 
months old mice 
(Wilcoxon test, 
**p<0.01, n = 10 each 
group). Of note, 
increased average 
proximity indicates 
poor performance. For 
visualization, inverse 
signed average 
proximity has been 
plotted B. Co-




along with aging in mouse blood from 13, 15 and 16 months (Wilcoxon test, *p<0.05, n = 10 each group). 
C. Eigen-expression is increased in the brain of young (n = 8) compared to old (n = 9) mice (Wilcoxon-Rank 
test, *p<0.05) näive B6J mice. D. Healthy human subjects were classified into three cross-sectional age 
groups (“30-40”, “41-53” and “54-65” years of age group). Weighted cognitive score (see Methods for 
details about calculation) from corresponding cross-sectional age group shows a significant decline in 
cognitive performance at “54-65” (n = 29) age group compared to “30-40” (n = 36) age group (Wilcoxon 
test, *p<0.05). Similar to mice, there was a trend in cognitive decline in “41-53” (n = 38) age group of human 
subjects compared to “30-40” year age group. E. “microRNA signature” eigen-expression from sex effect 
adjusted expression increased at “41-53” (n = 37) and “54-65” (n = 31) age groups compared to “30-40” 
year (n = 41) age group (Wilcoxon test, **p<0.01, *p < 0.05).  F. In APPS1 mice brain, model for 
Alzheimer´s disease, co-expression of the “microRNA signature” increased in transgenic mice compared to 
littermate controls at four months (n =6 each group) (Wilcoxon Rank test, *P<0.05, **P<0.01). G) 
“microRNA signature” co-expression in CSF (control, n = 16; MCI, n = 12) H. “microRNA signature” co-
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expression was also increased in plasma of human subjects who displayed mild cognitive impairment (n = 
6) compared to neurologically healthy subjects (n = 16). I. “microRNA signature” expression in blood 
(control, n = 23; MCI, n = 52). Age, gender, and effects from other surrogate variables as determined by sva 
were adjusted during the analysis of expression data (Wilcoxon Rank test). Box plot centers, lower and upper 
hinges represent the median, first and third quartiles respectively. 
 
 
The observation that the “microRNA signature” were also linked to neuron-related 
processes (see Table S7) prompted us to test their role in the brain more specifically. To 
this end we performed small RNA sequencing of the hippocampal sub-regions CA1, CA3 
and dentate gyrus (DG) and the anterior cingulate cortex (ACC) isolated from age-matched 
young and cognitively impaired old mice (Fig S5, Table S8, Table S9) followed by 
differential expression and comparative analysis across tissues as summarized in Fig S5. 
Similar to the data obtained in blood samples, expression of the “microRNA signature” 
was significantly increased in the brains of old mice (Fig 4C). 
 
To further substantialize the previous observation that our signature’s expression in blood 
changes prior to cognitive decline, we decided to investigate its expression in human cross-
sectional data. Thus, we recruited healthy human individuals aged between 30 and 65 years 
and collected blood samples and assessed how cognitive performance is affected by aging. 
Previous cross-sectional39 and longitudinal studies40 reported that few measures of 
cognitive performance required for everyday activities start to decline at the early 30s. 
While such a decline in a few cognitive domains is evident from 40 years, most of the 
them decline after 53 years of age, 41,42. Therefore, we divided the human mid-life age (40-
65 years)43 into two cross-sectional age groups “40-53” and “54-65” years of age. Next, 
we contrasted cognitive performance from these groups with that from “30-40” years age 
group. For cognitive measure, we investigated weighted cognitive performance in our 
PsyCourse cohort. We observed a significant decline in cognitive performance in only 
“54-65” age group (p < 0.05) (Fig 4D). Similar findings were reported in other studies 
40,41,44,45. Next, RNAs collected from individuals were subjected to small RNA sequencing. 
After adjusting gender bias, we observed increased co-expression of our “microRNA-
signature” at both “40-53” (cognitive decline was not significant at p < 0.05) and “54-65” 
(observed significant cognitive deficits) years group compared to “30-40” years group (Fig 
4E). Therefore, similar to mouse, in human, expression of this signature increased 
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significantly prior to significant decline in cognitive performance, and it remains over-
expressed during memory impairment. In summary, our data finds that “microRNA 
signature” expression increase in the blood of both mouse and human before the early 
onset of cognitive decline and its increased expression is maintained when cognitive 
deficits are detected.  
 
Analyses so far tested how this “microRNA signature” cluster expression changes during 
age-related memory decline. Next, we asked whether we would observe similar changes 
in age-matched disease conditions. Therefore, we investigated the co-expression of the 
signature in both blood and brain from mouse and human brain diseases. To this end, first, 
we analyzed the expression of the “microRNA signature” in APPS1 mice, a model for 
amyloid deposition and AD, at four months of age. Corroborating the previous findings, 
we observed increased expression of “microRNA signature” in the brain of four months 
old APP/PS1 mice compared with age-matched controls (Fig 4F).  Of note, at four months 
of age mice, APP/PS1 mice display mild cognitive impairment (MCI) 
(Agbemenyah….Fischer A. et al., unpublished).  Since the corresponding expression data 
from human MCI brain was not available, we investigated microRNA expression in MCI 
patient´s cerebrospinal fluid (CSF) as a proxy to the brain. After removing age, gender, 
and other surrogate covariates, we found increased co-expression of “microRNA 
signature” in CSF from human individuals with MCI compared with that of neurologically 
healthy subjects (Fig 4G, Jain,…Fischer A. et al. 2019, in press). Moreover, increased 
expression of “microRNA signature” was also observed in human plasma from MCI 
patients compared to age-matched healthy controls (Fig 4H). Furthermore, increased co-
expression of “microRNA signature” was observed in blood from MCI patients compared 
to healthy subjects (Fig 4I).  In summary, our data suggest that our circulating “microRNA 
signature” can inform about cognitive status at an earlier stage of cognitive deficit in 
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Manipulation of microRNA-181a-5p, member of “microRNA signature”, rescues early 
cognitive deficits in mice 
Having an early cognitive decline informative “microRNA signature”, we asked whether 
we could rescue early cognitive deficits. We reasoned that members of “signature 
microRNAs” might be a good choice for therapeutic interventions. To this effect, we were 
driven by studies showing that early synaptic dysfunction and neuronal loss are critical 
features for early cognitive defects 46,47. Thus, we sought therapeutic microRNA that is 
highly expressed in the brain and particularly enriched in neurons and could affect synaptic 
function. We first examined the neural cell-type expression of all three microRNAs from 
our “microRNA signature”48 and observed that microRNA-181a-5p was highly enriched 
in neurons (Fig 5A) and has been previously linked to be active at the synapse and regulate 
cognate synaptic mRNA expression49. Therefore, we decided to characterize the role of 
microRNA-181a-5p in cognition.  
 
Our qPCR data confirmed an increased expression of microRNA-181a-5p in both blood 
and brain of middle age compared to young subjects (Fig 5B).  Functional analysis using 
target genes revealed that microRNA-181a-5p is likely to regulate pathways linked to 
cognitive aging such as insulin, GPCR and MAPK signaling as well the function of the 
glutamate synapse and long-term potentiation (Fig 5C). These result point towards the link 
between microRNA-181a expression and cognition. We asked whether changes in 
microRNA-181a-5p expression could be causative or compensatory for early cognitive 
deficits.   To investigate this in great detail, we revisited the longitudinal cohort and 
observed that increased microRNA-  
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Fig 5: Circulating microRNA-181a levels, one of the microRNAs from our “microRNA signature”, is linked 
to memory performance in mice and humans 
A. Heat map showing the expression of these three microRNAs in different neural cell types based on the 
published dataset B. Bar plot showing qPCR results confirming the up-regulation of microRNA-181a-5p 
expression in brain (n = 6 each group, two-tailed t-test, p<0.05) and blood (n = 8 each group, two-tailed t-test, 
p<0.05) of old age when compared to young animals. C. microRNA-181a-5p related biological pathways D. 
Negative correlation between average proximity and microRNA-181a-5p expression from 15-16.5 months 
(Pearson´s correlation). A negative sign of average proximity has been used to make the plot. E. Correlation of 
microRNA-181a-5p levels in blood assayed via qPCR in 40 randomly selected individuals out of the PsyCourse 
cohort with cognitive score shows a negative correlation of microRNA-181a-5p with cognition (r = -0.41, P = 
0.006). Error bars indicate mean ± standard error mean.  
 
 
181a-5p expression levels in the blood is negatively correlated with cognitive performance 
(Fig 5D). Of note, at 16.5 months, mice exhibit increased inter-individual variability (Fig 
S6A), a finding that is also true for cognitive performance in humans50. Indeed, the link 
between microRNA-181a-5p and interindividual variability in healthy humans was 
confirmed (cor -0.41, ***p 0.006) via qPCR of 40 randomly selected individuals from our 
cohort (Fig 5E). Collectively, these data suggest that there is a negative association 
between increased microRNA-181a-5p expression and early cognitive deficit. Therefore, 
we hypothesized that increased microRNA-181a-5p expression could be causative for an 
early cognitive deficit. 
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Fig 6: microRNA mediated rescue of early cognitive deficit  
A. Primary hippocampal neurons (DIV10) were transfected with ncSiRNA/microRNA-181a-5p for 48h 
prior to the collection of cells followed by RNA extraction and next-generation sequencing. PCA plot of the 
sequenced data showing the biological difference (69% variance along with first principle component) 
between ncSiRNA and microRNA-181a-5p mimic treated cells (n = 6, each group). B. Heat map showing 
differentially expressed genes (adjusted p-value < 0.05) between two groups. Two hundred twelve genes 
were up-regulated, while 335 genes were down-regulated in microRNA-181a mimic treated neurons 
compared to control groups. Down-regulated genes are termed as “DownRegulatedCluster”. C. Gene 
ontology of down-regulated genes. Top 10 significant (adjusted p-value <0.05) biological processes are 
displayed. Learning, memory, and cognition related processes were top hits, suggesting that 
“DownRegulatedCluster” genes may be involved in cognition related pathways. D. Left panel: Experimental 
design. microRNA-181a-5p mimic or inhibitor oligonucleotides were injected into the CA1 of the dorsal 
hippocampus via microcannula prior to behavior testing. Middle panel: Escape latency is significantly 
reduced in mice injected with microRNA-181a-5p mimic when compared to the corresponding scramble 
control group (***p < 0.001, F = 41.4 for treatment; 2way ANOVA). Right panel:  During the probe test 
mice injected with microRNA-181a-5p mimic display reduced time in the target quadrant when compared 
to the scramble control group (*p = 0.012) (n = 10/group). E. Left panel: The escape latency of 16 months 
old mice injected with control oligonucleotides is reduced when compared to corresponding 3-months old 
mice (p < 0.0001, F = 17.1, 2 way ANOVA) or to 16 months old mice treated with microRNA-181a-5p 
inhibitor (p < 0.0001, F = 14.8, 2 way ANOVA) Right panel: 1way ANOVA revealed a significant group 
difference in the time spent in the target quadrant during the probe text (p < 0.001, F = 11.96) and post hoc 
analysis revealed that 16 months old mice injected with scramble control oligonucleotides were impaired 
when compared to corresponding 3-months old mice (***p < 0.0001) or 16 months old mice injected with 
microRNA-181a-5p inhibitors (**p = 0.006) (n = 10/group). Error bars indicate mean ± sem.  
 
 
To test this hypothesis to further detail, we decided to examine the role of microRNA-
181a-5p on neuronal function and memory directly. To this end, we overexpressed 
microRNA-181a mimic in hippocampal neurons and performed RNA sequencing. PCA 
revealed distinct expression patterns between control and mimic treated neuronal cells (Fig 
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6A). Further analysis revealed many significantly differentially expressed genes (Table 
S11) and as expected, the majority of the genes were down-regulated (335) (Fig 6B). 11% 
of these genes overlapped with confirmed targets of microRNA-181a deposited in 
miRTarBase. These target genes include histone methyltransferases Kmt2a and Kmt2c 
(Table S12).  GO-term analysis of the down-regulated genes revealed pathways linked to 
learning and memory (Fig 6C) further supporting the role of microRNA-181a in cognitive 
dysfunction. Interestingly, the genes down-regulated in response to elevated microRNA-
181a levels were highly overlapped with that from mouse models for cognitive disorders 
and human neurodegenerative diseases (Fig S8). These results imply a conserved 
microRNA-181a regulated network may underpin cognitive deficit in dementia. 
Altogether, these data provide evidence to claim that microRNA-181a is likely to cause 
cognitive deficits. 
 
To test this claim directly, we implanted microcannula into the CA1 region of the dorsal 
hippocampus of 3 months old mice and injected microRNA-181a-5p mimic 
oligonucleotides using an established protocol23 (see Fig 6D). Mice injected with a 
scrambled control oligonucleotide were used as control group. We used short 
oligonucleotides as control (scramble control) that would not interfere with endogenous 
transcript level for any gene. When subjected to water maze learning, mice injected with 
microRNA-181a-5p showed impairment in both learning and memory compared to control 
group (Fig 6D). Similar data were obtained using another memory test that measures 
associative contextual fear memories (Fig S9). These findings indicate that increased 
hippocampal microRNA-181a-5p levels contribute to memory impairment and suggest 
that in turn, reducing microRNA-181a-5p levels in the brain of aged mice could be a novel 
therapeutic approach to improve cognition. To test this hypothesis, we implanted 
microcannula into the dorsal hippocampus of 16 months old mice, the time point when we 
observed early cognitive deficit, and subsequently injected a microRNA-181a-5p inhibitor 
oligonucleotide. We had two control groups from 3 and 16-months old mice that were 
injected with a scrambled control oligonucleotide. Mice were then subjected to the water 
maze and fear-conditioning test to examine spatial reference and associative fear 
memories. While performance in the water maze was impaired when comparing scramble 
injected 16 to 3 months old mice, this effect was ameliorated in 16 months old mice 
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injected with the (Fig 6E). Similar data were observed in the fear-conditioning paradigm 
(Fig S9).  
 
In conclusion, we identify a “microRNA signature” that can inform about the early onset 
of cognitive deficits in both humans and mice. Moreover, our study demonstrates that early 
cognitive deficits in mice could be ameliorated through manipulation of one of the 
members of “microRNA signature”, namely, microRNA-181a-5p. We suggest that the 
analysis of the identified “microRNA signature” will be informative in ongoing and future 
prospective clinical and epidemiological studies investigating the cognitive function and 
brain plasticity in humans. Finally, our experimental approach is suitable for the 
identification of circulating biomarkers in other human diseases. Therefore, we encourage 
researchers to follow the experimental strategy outlined in our study by combining 
research on model system and humans, which will help to build an unprecedented database 
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Discussion  
There is increasing interest in the analysis of the blood microRNAome as biomarker for 
cognitive disease (e.g., see13 14-16 17 18). Our primary aim was to identify circulating 
microRNAs as non-invasive biomarkers that could diagnose early cognitive changes in 
dementia. We decided first to address this issue in humans. We reasoned that the cross-
sectional comparison between healthy and demented individuals would be suboptimal to 
discover informative biomarkers for early cognitive decline. Therefore, we adapted an 
alternative approach where we investigated total blood microRNAs in healthy human 
subjects who displayed asymptomatic cognitive variability in various neuropsychiatric 
tests. Our analysis revealed that microRNAs that significantly correlate with composite 
cognitive variabilities in healthy humans are likely to be involved in hypoxia. We have 
recently shown that hypoxia could drive the deregulation of cognition related changes in 
the brain and thereby can contribute to cognitive deficits (Md Rezaul Islam et al. 2019 
unpublished). Changes in microRNAs implicated in hypoxia may reflect the early 
metabolic changes occurring in the incipient demented brain. Concordantly, other studies 
have reported that hypoxia can be a risk factor of dementia51,52. Additionally, correlated 
microRNAs are also likely to be involved in aging, another risk factor of dementia. Given 
that the human participants in this study are young (age 25.95 ± 5.1 years), observing 
changes in aging-related microRNA expression and its association with cognition in this 
cohort is intriguing and prompted us to investigate further the effect of aging on 
microRNAs. 
 
To this end, we investigated blood microRNA expression and cognition in mice 
longitudinally. To analyze cognitive performance, we employed the Morris water maze 
test, a sensitive method to measure age-associated memory impairment in mice 36 and 
humans 33, that allows a repeated analysis of the same individual at multiple time points 
34,53. By positioning platform at different locations, we examined changes in cognitive 
performance over an extended time in mice. Memory impairment became most evident 
between 15 and 16.5 months of age. These data are in line with previous findings from 
cross-sectional studies, where memory impairment in mice was detected at 16 months36,54-
56. Our data from mice are also in line with findings in humans. Approaches to compare 
the relative age between different species suggest that mice of 15-16.5 months of age 
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represent 50-60 years age range in humans, a time window when memory decline sharply 
in the latter 50 57. In agreement with this, we observed a cognitive decline in humans aged 
54 and above (Fig 4D). Next, via a number of complementary computational approaches, 
we identified a “microRNA signature” in blood composed of three microRNAs 
(microRNA-181a-5p, microRNA-146a-5p, microRNA-148a-3p) that show increased co-
expression before and during early cognitive decline in both healthy mice and humans. 
Interestingly, the increased co-expression of “signature microRNAs” in blood was also 
observed during mild cognitive impairment (MCI) in patients with Alzheimer´s disease 
(AD). A similar pattern in expression was further observed in the AD brain, at least in 
mice. Thus, the distinct co-expression pattern of circulating “microRNA signature” could 
reflect changes occurring in the brain and more importantly could inform about early 
cognitive deficits.    
 
The question, however, remains why co-expression of these microRNAs levels similarly 
regulated in blood and the brain. To this end, it is interesting to note that microRNA-146a-
5p, microRNA-148a-3p, and microRNA-181a-5p are highly expressed in blood and 
brain58. All three microRNAs that belong to “microRNA signature”, have been shown to 
be expressed and playing critical roles in B-lymphocytes59-61. B-lymphocytes are known 
as “memory cells” that are characterized by the formation of an immune-synapse which 
shares structural similarity to the neuronal synapse and is critical for the regulation of T 
and B-cell function 62 63. It is therefore tempting to speculate that the co-expression of 
“microRNA signature” in neural cells and lymphocytes could be controlled via similar 
mechanisms that result in the early memory decline. Moreover, changes in the adaptive 
immune system have been linked to memory decline and neurodegeneration 64 65. Future 
research will address the role of the immune system on modulating the expression of the 
“microRNA signature”. However, the first evidence for this hypothesis stems from the fact 
that the promoter of microRNA-181a harbors, for example, binding motifs for NF-κB 
(Table S13). Moreover, previous studies have shown that microRNA-146a-5p expression 
can be regulated by NF-κB60,66. Of note, this transcription factor has been linked to 
adaptive immunity and immune synapse function 67,68 as well as memory formation 69 37 
70 and Alzheimer’s disease 71. Another possible scenario is that the observed changes in 
“microRNA signature” co-expression reflect age-related changes in lymphocyte numbers. 
This can, however, not explain the increased co-expression of “microRNA signature” in 
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age-matched individuals and moreover, lymphocyte number is known to generally 
decrease with increasing age  72. Thus, a simple overall change in blood cell number cannot 
explain the observed increase in circulating “microRNA signature” co-expression. It is 
also possible that circulating levels of “microRNA signature” represent an increased co-
expression pattern in other organs. For example, microRNAs can be released from cells 
via exosomes73, and brain-derived exosomes have been identified in circulation 74. Indeed, 
all the members of the “microRNA signature” are present in CSF exosomes (unpublished 
data) and we observed increased co-expression of the “microRNA signature” in this 
biological fluid (Fig 4G). Moreover, increased expression of “microRNA signature” was 
also observed in the plasma of MCI patients, highlighting a consistent expression pattern 
of the “microRNA signature” in various biological fluids. The method applied in this study 
to isolate RNA from blood, however, does not allow to identify the precise source of the 
detected microRNAs. Thus, further studies are required to elucidate the exact mechanisms 
that lead to increased co-expression of “microRNA signature” levels in both blood and 
brain. 
 
As an exemplar candidate from this cluster of three microRNAs, we further studied 
microRNA-181a-5p mechanistically. Conclusive evidence that microRNA-181a-5p is 
causative to cognitive decline was provided by our data showing that increasing 
microRNA-181a-5p levels in the dorsal hippocampus of young mice impaired both spatial 
reference and associative learning. By contrast, two recent studies have reported that miR-
181a-5p is important for memory formation75,76. However, in support of our observation, 
elevated levels of microRNA-181a-5p were implicated in cell death after cerebral 
ischemia, whereas low levels were associated with neuronal survival 77 78 79. These 
supporting data are also in line with our observation that microRNA-181a-5p levels in the 
brain are highest in neurons and that pathways linked to experimentally validated 
microRNA-181a-5p targets represent key processes linked to synaptic plasticity and 
neuronal integrity. Indeed, microRNA-181a-5p was found in synapses, where it controls 
surface levels of key mRNAs linked to memory function such as AMPA-type glutamate 
receptor 80 or CamKII 81. As shown in this study, the potential of microRNA-181a-5p in 
regulating a conserved gene network in general memory disorders could explain, at least 
in part, how increased expression of microRNA-181a-5p can contribute to general 
cognitive deficits. It is thus interesting to note that microRNA-181a-5p levels in PBMCs 
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are correlated with an increased genetic risk for autistic phenotypes in schizophrenia 
patients that are characterized by impaired cognition 82. Interestingly, by decreasing levels 
of microRNA-181a-5p levels in the hippocampus of aged mice improved memory 
function. These findings are in agreement with previous data showing that calorie 
restriction led to a down-regulation of microRNA-181a-5p, which was linked to improved 
neuronal integrity 83. These data are of particular importance since calorie restriction 
ameliorates age-associated memory impairment 84,85.  
 
In conclusion, our study suggests that a cluster of three circulating “microRNA signature” 
could be a suitable marker of early cognitive changes in dementia. Moreover, it highlights 
the potential of microRNA-181a inhibitor as therapeutic intervention in early dementia. 
To the best of our knowledge, a longitudinal cognitive phenotyping together with analyses 
of blood microRNAome has not been conducted so far. Our experimental approach can be 
adapted to other longitudinal studies in mice in the context of disease progression and 
therapeutic intervention. In fact, on the basis of the data presented here we have initiated 
the consequent analysis of circulating microRNAs within the cohort studies of the German 
Center for Neurodegenerative Diseases (www.dzne.de), the PsyCourse cohort 
(http://www.psycourse.de/index-en.html) and the corresponding animal models with the 
aim to construct a database that will allow unprecedented comparison and cross-
correlation of data from humans and corresponding animal models. Considering that the 
current therapeutic arsenal to treat, for example, AD might be effective if treatment can be 
initiated early, circulating “microRNA signature” biomarker could help to improve the 
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Materials and Methods 
Animals 
Naive male C57B/6J mice were obtained from Janvier. All animals were housed in 
standard cages on 12h/12h light/dark cycle with food and water ad libitum. All 
experiments were performed according to the protocols approved by FELASA. Mice of 3 
months and 18 months were sacrificed by cervical dislocation and whole brain was isolated 
in ice-cold Dulbecco's Phosphate Buffered Salt (DPBS, PAN-biotech GmbH) 
supplemented with EDTA-free protease inhibitor cocktail (Roche). The ACC, CA1, CA3 
and DG regions were isolated, snap frozen in liquid nitrogen and stored at -80 °C. To 
follow the aging process in individual mouse, animals at age of 12 months were divided 
into two groups: normal aging (A) and water-maze aging (WM). Mice performing water 
maze related behavioral experiments belonged to water maze group and the rest were in 
control group. For water maze group, we started longitudinal experiment with 12 mice, 
but during analysis two mice were removed as outliers to have same 10 mice throughout 
different time points. All mice at 12 months age (before separating into two groups and 
starting behavioral tests) were considered as control for comparison of small RNA 




All experiments reported in this study were approved by the local ethics committee. We 
analyzed healthy individuals that participated in PsyCourse study (Budde et al., in press;  
https://www.preprints.org/manuscript/201710.0169/v1). Briefly, adult healthy individuals 
were recruited for this study as control participants. The following neuropsychological 
tests were performed: Digit-Span (forward and backward); Digit-Symbol-Test, Trail-
Making-Test, and the Multiple-Choice Vocabulary Intelligence Test (MWT-B) for details 
see Budde et al. (in press). Samples were excluded from the study if they had ever been 
detected as patient for mental and behavior disorder of ICD-10 diagnoses. The study was 
approved by the local ethics committee that was in accordance with the declaration of 
Helsinki. A composite score considering all the psychological tests was calculated similar 
to 86. Briefly, for exploratory factor analysis on cognitive test scores, number of optimum 
latent factors (n = 3) was determined based on model fit score RMSEA 0.02 and parallel 
analysis 87. Next, exploratory factor analysis was performed and tests were grouped into 
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three cognitive domains. Based on the low loadings (<0.4) on the factors, multiple choice 
vocabulary intelligence and trail making test error-A tests were discarded from the 
analysis. First domain was measured by Trail making tests and Digit Symbol test. Similar 
factor analysis based domain was reported and termed as executive function domain in 
previous study 88.  Second domain comprised of Digits forward, Digits backward and could 
be described as “working memory” domain. Errors in Trail making tests (part B) were part 
of the third cognitive domain. Having the cognitive domains defined, individual test score 
was standardized by subtracting the mean from the score and dividing by the standard 
deviation. Next, an average domain specific score was calculated from the standardized 
scores of the tests belonging to the domain. Finally, domain specific cumulative scores 
were averaged to obtain a global weighted cognitive performance score. Higher and lower 
weighted score represent good and poor performance respectively.  
 
Water maze  
A standard water maze setting was used to conduct Morris-water maze experiment as 
previous study35. At 12 months, first water maze training was performed to habituate mice 
with the training environment. Animals were tested for visual performance by putting a 
colored cue on the platform.  In order to do the spatial memory-learning test and to check 
cognitive flexibility, during the later training sessions at 13.5, 15 months and 16.5 months 
platform was put at the center of a new quadrant. However, the position of platform was 
kept unchanged throughout the corresponding training session. Different visual cues on 
four sites of the pool were not changed during training trials either.  
The swimming behavior of the mice was recorded by a camera set on top of the water pool 
and was analyzed by VideoMot2 (TSE). At each training session, mice were trained to 
swim to the hidden platform in four daily trials, starting from pseudorandomly varied 
locations. Each trial consisted of 60 seconds. If mouse failed to find the platform in due 
time it was gently guided to it. Once reaching the platform, the mouse was allowed to have 
rest for 15 seconds. After four consecutive trials per day, each mouse was returned to its 
home cage where it rested until the next day of training. Sixty seconds long probe trial was 
performed without the platform after each training session at a given month. After last 
probe test performed at 16.5 months, animals were tested for visual acuity again.   
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For data analysis, features from TSE VideoMot2 software were used. For occupancy plot, 
50 x 50 grids defined a bin and number of mouse crossing through each grid was summed 
up. Densities were calculated from the ratio of total number of crossings through each grid 
and total number of crossings in the bin. For plotting, a smoothened technique was applied 
to the densities and minimum and maximum densities out of all experimental groups were 
taken into consideration during normalization step.  
For in depth feature analysis from water maze data, a modified version of MUST-C 
algorithm was used 32. In addition to the features described in original paper, we extracted 
few extra features from raw water maze data including total coverage, distance from 
centroid to platform and path efficiency.  The definition of the features extracted from 
water maze data are as follows: 
a) Average proximity to platform: mean of Euclidean distances from all positions to the 
platform b) Distance from centroid to platform: Euclidean distance between center of all 
positions and platform c) Sum of absolute angles: sum of angles between pairs of 
sequential vectors d) Mean distance from perimeter: mean distance to the closest point on 
the pool`s perimeter e) Total duration: total time mice spent in searching the platform f) 
Number of quadrant changes: total number of quadrant changes during trial g) Maximal 
time at one quadrant: percentage of time spent in a single quadrant h) Sum of relative 
angles: positive and negative angles are marked from positive and negative movements 
along X axis respectively i) Cumulative angle along Y axis: similar to angles along X axis, 
relative angles along Y axis is calculated j) Platform crossings: number of crossings of the 
platform region (probe test) k)Variance of distance from perimeter: variance of Euclidean 
distances from the pool´s perimeter l) mean velocity: ratio between total distance and total 
time spent m)Distance traveled: sum of Euclidean distance between each pair of sequential 
locations n) Total coverage: ratio between area of convex hull of all points and the area of 
the pool o) Local densities: mean distance between all pairs (x,y coordinates) of locations 
in the trial p) Variance of distance to platform: variance of Euclidean distance from all 
positions to the platform q) Path efficiency: ratio of the path length to the Euclidean 
distance between starting and endpoints. Path length is sum of Euclidean distances 
between all consecutive points in the trial.  
 
Based on all these features scatter plots were generated, and one of the following search 
strategies was assigned to each trial of the training session. Different scores were assigned 
to these different strategies ranging from 0 to 10. Briefly, direct, corrected, focused and 
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short chaining represent higher cognition and therefore were given score of 10,9,9 and 8 
respectively. Other strategies were given scores as follows: circling = 5, accidental circling 
= 4 long chaining =2, focused false = 1, random = 0, thigmotaxis = 0 and passivity = 0. 
Cumulative scores during training and probe test were calculated from sum of all strategic 
scores across training trials and during probe test respectively. Since during probe trial 
there was no platform in water maze, only focused, focused circling, circling and random 
strategies could be defined.  
 
Fear conditioning test 
Fear conditioning test was performed using TSE fear conditioning system. Mice were 
allowed to explore the context for 3 min prior to experiencing mild electric foot shock 
(constant current, 0.5 mA) for 2 s. After 24 hours, they were introduced to the same context 
for 3 min without receiving any foot-shock and associative memory was checked by 
inspecting their freezing behavior.  
 
Collection of Blood from mice and purification of total RNA from blood and brain 
sub-regions 
For APPS1 mice, peripheral blood was collected through cardiac puncture and stored in 
tubes provided by RNeasy Protect Animal Blood System (Qiagen, Hilden, Germany). For 
mice used in longitudinal study, blood was collected from retro orbital sinus of all mice 
for first time at 12 months age before starting any behavioral experiment. Next blood 
collections were done after 24 hours of finishing probe tests at 13.5, 15 and 16.5 months. 
In summary, individual mouse was anesthetized with Isofluran (1.8%) for 2-3 minutes. 
Afterwards, 150-200 µl blood was collected from the orbital sinus of animals using a 
heparinized glass micro capillary and stored.in RNeasy Protect Animal Blood System 
tubes. Each time blood was collected from alternative eyes. The blood tubes were allowed 
to stand at room temperature for 24 hours, and then stored at -20°C. Purification of total 
RNA from blood was performed following the manual of RNeasy Animal Blood protect 
kit (Qiagen, Hilden, Germany). Briefly, blood tubes were centrifuged for 3 min at 5000xg 
at room temperature. After removing the supernatant without disturbing pellet, 1ml of 
RNAse-free water was added. The solution was vortexed and centrifuged in the same 
condition as mentioned above.  Supernatant was discarded and 240 µl Buffer RSB was 
added to pellets. After re-suspending the pellet properly, appropriate amount of buffer 
RBT and Proteinase K were added and the solution was incubated for 10 minutes at 55°C. 
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Next, the solution was applied on the membrane of the QIAshredder spin column and 
centrifuged for 3 minutes at the maximum speed. After centrifugation 1.5 volume of 100% 
Ethanol was added to the flow-through. Later, the solution was applied into a 2 ml RNeasy 
MinElute Spin column and centrifuged for 1 min at 10,000xg. The membrane of spin 
column was washed once with 350 µl of Buffer RWT and DNase treatment was performed 
for 15 min at room temperature. Next, 350 µl of buffer RWT was added to the column 
followed by centrifugation for 15 seconds at 10,000xg.  Column was washed with 500 µl 
Buffer RPE (centrifugation for 15 seconds, at 10,000xg, at room temperature). The final 
wash was performed with freshly prepared 80% ethanol followed by centrifugation for 2 
minutes at 10,000xg. RNA was eluted with REB buffer after a short centrifugation 
(10,000xg, 1 minute). Extracted RNA was incubated at 65°C for 5 minutes and 
immediately placed on ice.  Concentration of RNA was measured on Nanodrop and 
isolated RNA was stored at -80°c for future use. Total RNA extraction from mouse ACC, 
dentate gyrus, CA1 and CA3 were conducted using Tri reagent (Tri Reagent, Sigma-
Aldrich,Germany) according to manufacturer’s instruction.  
 
Blood collection in humans 
Blood was collected from the median cubital vein. Before collection the collection tubes were 
stored at 18-25°C.  For the collection of blood via PAXgene tubes 2.7ml of blood were filled 
into the tube that was subsequently gently inverted 10 times. Tubes were stored for 2h at room 
temperature and then transferred to -20°C for 24-72h before being stored at -80°C until further 
processing. For the isolation of PBMCs blood was collected in CPT tubes that were 
subsequently inverted 8 times and then centrifuged for 30 min (1700xg) at room temperature. 
By using a pipette, plasma was removed (until 1cm above the white lymphocyte layer). The 
white lymphocyte layer was then transferred into a 15 ml Falcon-tube using a pipette. 
Subsequently the tube was filled with up to 15 ml with PBS and gently inverted 5 times. The 
Falcon tube was centrifuged for 15 min (300xg, with brake) at room temperature and the 
supernatant was discarded and the pellet re-suspended in 15 ml PBS. These steps were repeated 
in total 3 times. The cell pellet was eventually re-suspended in 2 ml of PBS and frozen in liquid 
nitrogen before being stored at -80°C. For plasma samples, blood was collected into EDTA-
plasma tubes and centrifuged from 10 min (2000 x g, without brake) at room temperature. The 
supernatant was aliquoted into cryo-tubes into and stored within 30 min at -80°C. Exosomes 
were isolated from plasma via a number of subsequent centrifugation steps at 4°C: 3500xg for 
10 min, two times 4500xg for 10 min, 10 000xg for 30 min and 100 000xg for 60 min. The 
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100,000xg  pellet was washed once with phosphate-buffered saline (PBS) at 100 000g for 60 
min before re-suspension in PBS89 
 
High-throughput Small RNA sequencing and bioinformatics analysis  
Next generation sequencing of the RNA from collected blood samples from mouse were 
performed using TruSeq® Small RNA kit according to manufacturer´s protocol (Illumina, 
San Diego, CA, USA). Briefly, 100 ng RNA was used as starting material followed by 
adapter ligation and primer hybridization. First strand of cDNA was generated followed 
by PCR enrichment. Libraries were pooled and PAGE was run for size selection. For small 
RNAome ~150 bp band was cut and used for library quantification after purification. A 
final library concentration of 2 nM was used for sequencing. Sequencing was performed 
using a 50-bp single read setup on the Illumina HiSeq 2000 platform. Demultiplexing was 
done using Illumina CASAVA 1.8. For human samples, sequencing libraries were 
prepared using NEBNext® small RNA library preparation kit according to manufacturer´s 
instruction.  
 
Sequencing adapters were removed using cutadapt-1.8.1 90. Sequencing quality including 
total number of reads, percentage of GC content, sequence quality per base, N content per 
base, sequence length distribution, duplication levels, overrepresented sequences and 
Kmer content was investigated using FastQC v0.11.5 
(http://www.bioinformatics.babraham. ac.uk/projects/fastqc/).   
 
For quantification of mature microRNAs, miRDeep2 was primarily used. Briefly, mouse 
(mm10) and human (hg38) genome sequence were retrieved from UCSC 
(https://genome.ucsc.edu/) Genome Browser and corresponding genomic index files were 
created using Bowtie-build tool (version 1.12) with default options. Sequencing reads were 
mapped to the reference genome using mapper.pl script with default settings in the 
miRDeep2 package. Reads less than 18 nucleotides were discarded and miRDeep2 module 
with default options was used to identify known and novel microRNAs in sequencing data. 
To quantify known microRNAs, sequencing reads, the known mature microRNAs and 
optionally its star sequences for mouse were mapped against the known precursor 
microRNAs for reference genome documented in miRBase (Release 21), allowing 0 
mismatch. A read was assumed to represent a sequenced mature microRNA, if it fell within 
the same position on the precursor as mature microRNA, plus 2 nt upstream and 5 nt 
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downstream. For the prediction of novel microRNAs, mature microRNAs in Rattus 
norvegicus (miRBase release 21) were provided as related species for mouse. On the other 
hand, mature microRNAs in Gorilla gorilla, Pongo pygmaeus, Pan troglodytes (miRBase 
release 21) were provided as related species for human. However, novel microRNAs are 
not discussed in the current study. Samples were evaluated with respect to mapping quality 
and library size and only those with good mapping score and comparable library size were 
considered in downstream analysis. In total, for home-cage group we had sequencing data 
from 10 mice per time point while in water maze group sequencing data from 9, 10, 6 and 
10 animals were analyzed for 12, 13.5, 15 and 16 months, respectively.  
 
Differential expression analysis 
Prior to any differential analysis, microRNAs (from miRBase release 21) with raw read 
counts ≥ 5 in at least 50% of studied samples were selected for further analysis. Unwanted 
variation factors were estimated based on reads in replicate samples and these variants 
were removed from sequencing data using RUVSeq (Risso, Dudoit et al. 2014). 
Differential expression analysis was performed using DESeq2 (Love, Huber et al. 2014). 
microRNAs having adjusted p value < 0.05 were considered as significantly deregulated.  
 
Rank-rank hypergeometric overlap analysis 
The significance overlap of expressed microRNAs between two cohorts was calculated 
using the rank-rank hypergeometric test 91. Briefly, microRNAs were ranked by 
expression, placing the most expressed microRNA at the top and the least expressed at the 
bottom of the list. Number of overlapping microRNAs between two cohorts was counted 
at every 10th combination, and Fisher’s exact test was used to calculate significance of the 
overlap and later was corrected after multiple statistical adjustments.  
 
Clustering of Expression Profiles 
For aging and WM groups, small RNAs were clustered according to their expression 
profiles using a fuzzy c-means algorithm in R based package e1071 v1.6-2. The optimum 
number of clusters was determined using several cluster validation indexes as described in 
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Weighted gene co-expression analysis of microRNAs 
MicroRNAs that are highly correlated in learning group were identified and summarized 
with a modular eigengene profile using the weighted gene co-expression network analysis 
(WGCNA) package (version 1.61) in R.  Briefly, normalized and log (base 2) transformed 
microRNA expression data was used to calculate pair-wise correlations between 
microRNAs. Next a soft threshold power of 8 was chosen based on approximate scale-free 
topology and used to calculate pair-wise topological overlap between microRNAs in order 
to construct a signed microRNA network. Modules of co-expressed microRNAs with a 
minimum module size of 20 was later identified using cutreeDynamic function with 
following parameters: method = “hybrid”, deepSplit =3, pamRespectsDendro =T, 
pamStage = T. Closely related module were merged using dissimilarity correlation 
threshold of 0.15. Different modules were summarized as network of modular eigengenes, 
(MEs) which were then correlated with weighted cognitive score calculated from eight 
different cognitive tests in human as mentioned above. Pearson correlation of MEs and 
each of these features was plotted as heat map and identified three modules (brown, blue 
and turquoise) that significantly (p <0.05) correlate with weighted cognitive performance.  
 
Machine learning based microRNA feature selection and prediction 
Normalized microRNA sequencing data was used to train a machine learning random 
forest regressor. A set of 17 features derived from the Morris Water Maze experiments 
were computed, namely average proximity to platform, centroid, cumulative angles, mean 
distance to edge, total duration, number of quadrant changes, maximum quadrant, relative 
angles, cumulative angle along y axis, platform crossings, pool edge variation, mean 
velocity, cumulative distance, total coverage, local densities, variation of distance to 
platform and path efficiency.  An in-house data analysis toolbox was used to compute the 
aforementioned features. These phenotypic features were compressed into a single 
quantity by means of their first principal component projection (i.e. PCA’s first 
component) and used as a univariate score for representing cognitive ability. The cognitive 
score was used along with the 55-microRNA count signatures to train a RF regressor, with 
the cognitive score being the outcome variable and the “microRNA signature”, the 
predictors. Given our interest on determining the best (sub)-set of microRNAs that link to 
the cognitive score, three independent RF regression models were trained, each one using 
different feature selection algorithms: boostrapping, leave-one-out cross-validating and 
using a univariate filter. Parameters for bootstrapping were set to number=250, repeats=1 
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and p=0.75; whereas for the univariate filter, number=5 and repeats=20. Leave-one-out 
cross validation parameters were number=1, repeats=1 and p=0.75. Analyses were 
implemented using R (v.3.3.1) with the package Caret (v.6.0.76). 
 
Gene ontology and pathway analysis of microRNA target genes 
All experimentally validated microRNA target genes in mouse were retrieved from 
miRTarBase v-6.1 (http://mirtarbase.mbc.nctu.edu.tw/). Gene ontology and pathway 
analysis was performed using ClueGO v.2.2.6 92 platform in Cytoscape v.3.3 93. ClueGO 
functional analysis was performed using all experimental evidences (inferred from 
experiment, direct assay, physical interaction, mutant phenotype, genetic interaction and 
expression pattern) available. Enrichment of GO terms for set of microRNA cognate target 
genes was assessed with a right-sided hypergeometric statistical analysis which provides 
a p-value that was further corrected using a Bonferroni step down method. Only GO terms 
with corrected p-value<0.05 were considered as significant. Files were prepared using in-
house R script. 
 
Lipid nanoparticle packaging of microRNA 
Small RNAs (sRNAs) were packaged into lipid nanoparticles using SPARK using Neuro9 
kit according to manufacturer´s instruction. Briefly, re-constituted sRNA in nucleic acid 
storage buffer was mixed with formulation buffer 1 to have final concentration of sRNA 
of 930 ug/mL. Next, formulation buffer 2, lipid nanoparticles and sRNA-formulation 
buffer were put in defined chamber of Spark Cartridge and a NanoAssemblr Spark was 
used to mix and generate lipid nanoparticles packaging sRNAs. All steps were followed 
in a sterile condition. Prepared lipid nanoparticles containing sRNAs were stored at 4°c 
before further use.  
 
Primary Hippocampal neuronal culture  
Whole hippocampus was micro-dissected from the E16.5 CD1 mice embryos and digested for 
13 minutes at 37°c in 4.5 ml pre-warmed PBS mixed with 2.5% trypsin. After digestion, 
dissociated cells were washed three times with processing media containing DMEM (Merck, 
cat. FG0445), 10% FBS (GIBCO, cat. 10500064)  and 1% penicillin/streptomycin (PanReac 
AppliChem, cat. A8943). Cells were resuspended in the processing media and centrifuged at 
300xg for 5 minutes to get cell pellet. Next, cell pellet was re-suspended in maintenance media 
containing neuroabasal, 1% penicillin/streptomycin, 2% B27 (GIBCO, cat. 17504001) and 1% 
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glutamax (Thermofisher Scientific, cat. 35050061) and plated in a 24 well PDL pre-coated 
plate at 130,0000 cells/well (DIV0). Neuronal enriched cultured was maintained at 37°c and 
on DIV10, cells were transfected with microRNA-181a-5p mimic/negative control siRNA. 48 




Hippocampal injections to CA1 region were performed as described previously 
(Sananbenesi et al, 2007)23. In summary, mice were anaesthetized and microcannulae 
(gauges of the guide and injection cannula being 1.5 and 0.5 mm respectively) were 
inserted into the hippocampus using the following coordinates: 1.0 mm posterior to the 
bregma; 1.0 mm lateral and 1.5 mm ventral from midline. microRNA mimics and 
inhibitors were injected bilaterally (1 µl, at a rate of 0.3 µl/min per side).  
 
Quantitative RT-PCR for microRNA and target genes 
Quantification of mature microRNA-181a-5p in blood was accomplished using miScript 
Primer Assays kit (Qiagen, USA) on Roche LightCycler 480 instrument according to 
manufacturer`s instruction. For longitudinal samples in mice, mouse microRNA-29b-1 
mature sequence was used as an internal control. For microRNA-181a-5p quantification 
from blood in young and old mice, human RNU6B was used as housekeeping gene. Real 
time PCR (q-PCR) primers for microRNA-181a-5p target genes MAP2k1, Insulin Growth 
Factor 1 Receptor (IGF1r) and AMPA2 (alpha 2), ionotropic glutamate receptor (Gria2) 
were designed using Universal probe library Assay Design Center and were purchased 
from Sigma. cDNA was synthesized using the Transcriptor High Fidelity cDNA Synthesis 
Kit (Roche) and real-time quantification was performed using Roche Universal Probe 
Library (UPL) probes. Primer sequences and UPL probe numbers for all the genes are 
given in Table S14. Results were normalized to the expression of internal control 
Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) gene. Relative gene expression was 
analyzed by 2−ddCt method 94. 
 
Statistics 
Statistical analysis for behavioral and molecular studies was performed using GraphPad 
Prism 7. Details of statistical analysis, methods, and parameters are given in the figure 
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legends. Statistical tests performed were based on data structure and included as follows: 
one‐way, two‐way, or repeated‐measures analysis of variance, Student's t‐test and F-
test. 
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Fig S1. Analyzing circulating microRNAs in mice and humans.  
A. Experimental design of the pilot experiment. We analyzed the circulating microRNA expression profiles 
in blood samples obtained from healthy individuals at two different time points. RNA was isolated from 
blood using four different approaches, namely via PAXgene tubes (Qiagen), from peripheral blood 
monocytes (PBMC), plasma, and blood exosomes. B. All samples were subjected to small RNA sequencing. 
The Venn diagram shows the microRNAs detected via the four different approaches at time point 1. In total, 
125 microRNAs were commonly detected in blood via all four methods. C. Heat map showing the correlation 
of small RNA-seq data obtained from blood at time point 1 and 2. When comparing the expression of blood 
microRNAs at time point 1 vs. time point 2 we observed that most consistent results were obtained when 
small RNA sequencing was performed on RNA isolated via PAXgene tubes or from PBMCs D. Considering 
that the isolation of RNA from blood via PAXgene tubes is comparatively easy and can also be performed 
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in a clinical setting without access to a wet lab we decided to focus on this approach and replicate our 
observation in an independent experiment. To this end, PAXgene blood samples were collected from an 
additional group of individuals at two different time points. Also, in this replication cohort, the microRNA 
expression amongst individuals and amongst time points 1 and 2 was highly correlated as shown by the 
corresponding heat map. E. According to the manufacturer, the RNAeasy system (Qiagen) for the isolation 
of RNA from the blood of small animals is based on the same chemistry as the PAXgene (Qiagen) system 
for human blood collection suggesting that data obtained from humans via PAXgene tubes and mice via the 
RNAeasy kit would allow for optimal comparison. To test this more specifically, we established a protocol 
for the longitudinal collection of blood from mice followed by small RNA sequencing (see methods for 
details). Next, we performed a pilot experiment in mice to test our protocol of blood collection followed by 
small RNA sequencing. The upper panel depicts the schematic outline of the pilot experiment (n = 
10/cohort). We collected blood from a cohort of 12 months old mice and store the samples at -80°c (cohort 
1). Two months later, the exact procedure was repeated in another cohort of 12 months old mice (cohort 2). 
RNA samples from cohort 1 and cohort 2 were then subjected to small RNA sequencing. The lower panel 
shows a rank-rank hypergeometric overlap (RRHO) analysis that revealed that the expression of microRNAs 
detected in cohort 1 and cohort 2 was highly overlapped (rho = 0.9). Each pixel represents the overlap 
between two cohorts, and color-coded according to adjusted –log10 p-value of a hyper-geometric test. F. 
We tested to what extent the circulating microRNAome defined via the above-described methods in mice is 
representative to that of humans. To this end we compared samples collected via PAXgene tubes from 
humans around 40 years of age (38+/- 11 year, n = 19) to samples obtained via the RNAeasy kit from mice 
at 12 month of age, since 12-month of age in mice is believed to relate to 40 years of age in humans 95. Our 
data reveals that the majority of the microRNAs detected in humans PAXgene blood samples is also 
observed in mice. Even more impressive is the fact that the corresponding expression levels of the circulating 
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Fig S2. Behavior and sequencing data analysis from longitudinal experiments.  
Blood was collected from anesthetized mouse via the retro-orbital sinus. Alternate eyes were used during blood 
collection at different time points. A visual cue assisted probe test (schematically indicated in the left panel) was 
performed to check visual performance of mice after habituation training at 12 months (test1, n=10) and after 
finishing probe test at 16.5 months (test2, n=10). In this test mice are able to see the platform and thus do not need 
to rely on spatial reference memory to find the platform. Compromised vision would impair the performance in 
this test. There is no significant difference in performance (paired t-test, two-tailed, p value 0.59) between two 
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Fig S3. Aging associated microRNA changes in the “home-cage” group 
A. Outline of the experiment in home-cage group. Blood was collected at the given time points, but no behavioral 
test was performed. B. Heat map showing differentially expressed microRNAs during aging in the home-cage 
group. C. Age-dependent deregulated microRNAs separate into two main clusters: i) upregulated at late age ii) 
down-regulated at late age. D. Expression cluster of microRNAs that do not change during aging in the home-
cage and learning group. 
E. (Left panel) Venn diagram showing that 55 microRNAs are commonly deregulated during aging in the learning 
and home-cage groups. (Right panel) The expression of the 55 microRNAs commonly regulated during aging in 
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Fig S4. Principle component analysis of the features measured during spatial reference learning in the 
water maze task.  
PCA plot using the seventeen different variables used to measure performance in the water maze test. First two 
components (PC1 and PC2) could explain sixty percent of the variation in data. The length of the arrows 
indicates how much variability is explained by each of the 17 learning strategies.   
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Fig S5. The microRNAome of learning-related brain regions in the aging mouse brain 
Previous genome-wide microRNAome data on brain aging 96-98 are characterized by low sample size, include 
array approaches limited by probe design and focused on whole brain or whole hippocampal tissue. Thus, 
we performed small RNA sequencing of the hippocampal sub-regions CA1, CA3 and dentate gyrus (DG) 
and the anterior cingulate cortex (ACC) isolated from young (3 months of age) and cognitively impaired old 
(18 months of age) mice.  A. Pearson’s coefficient-based correlation followed by unsupervised clustering of 
all small RNA-seq data from different brain regions (ACC; CA1; CA3; DG) in young mice reveals brain-
region specific expression of the microRNAs that was particularly obvious for the ACC vs. the hippocampal 
sub-regions and the DG vs. CA1 and CA3. These region-specific differences were, however, mainly 
attributed to different expression values since the majority of the microRNAs, namely 176 microRNAs, 
could be detected at reliable levels in all investigated brain regions (see also Table S4). B. Volcano plots 
showing differential expression of microRNAs in the different brain regions when comparing young vs. old 
mice. C. Bar plots showing the number of up and down-regulated microRNAs in the investigated brain 
regions. D. Comparison of gene ontology and functional pathways of experimentally confirmed target genes 
of the deregulated microRNAs in the investigated brain regions. Pathways are generally linked to neuronal 
death and longevity pathways. E. Venn diagram showing that 57 microRNAs are commonly deregulated in 
the aging brain. F. Heat map showing hierarchical clustering of the 57 commonly deregulated microRNAs 
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based on Log2 fold change Z score. G. Top 20 biological processes affected by the confirmed target genes 











Fig S6. Inter-individual variability in mouse and healthy human individuals 
A. With increasing age, the inter-individual variability in cognitive function, displayed here as average proximity 
to platform during the water maze probe test increases (n = 10; F test, p = 0.02; 16.5 months compared to 13.5 
months). Variance is calculated using var.test function in R. Error indicate SEM. B. Variability in average 
proximity was noted in an independent cohort of 16.5 months old mice (n = 29) C. The data depicts the variability 
in cognitive performance amongst the control individuals of the PsyCourse cohort (n =132). Cognitive score was 
calculated on the basis of 8 neuropsychological tests (See methods for details). The variability in cognitive abilities 
allowed us to test the correlation of microRNAs in blood with cognitive function. 
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Fig S7. microRNA-181a regulating conserved gene network in different models of memory disorders.  
A. microRNA-181a-5p regulating cluster “DownRegulatedCluster” is further down-regulated in brain of CKp25 
mice (2 weeeks and 6 weeks), model of AD pathology99. Besides mice, the same cluster of genes is downregulated 
in human subjects with PD (Parkinson´s Disease)100. Intriguingly, proteins of the genes belonging to 
“DownmiR181aTargetCluster” were also downregulated in AD human compared to neurologically healthy 
subjects101. B. “DownRegulatedCluster” is also significantly down-regulated in Kat2aKO102 and Kmt2aKO103 
mice compared to the corresponding controls. Color bar is indicating the Odds ratio in log2 scale that measures 
the strength of overlap between two lists. Log2 odds ratio ≤ 0 indicates no overlap while the greater the value than 






Fig S8. microRNA-181a-5p regulates consolidation of associative fear memories 
A. 3 months old mice (3 Mo) were injected with either microRNA-181a-5p (microRNA-181a) mimic or scrambles 
control oligonucleotides into the dorsal hippocampus and subsequently subjected to contextual fear conditioning. 
During the memory test performed 24h later mice injected with the microRNA-181a-5p mimic displayed 
significantly less freezing behavior indicate of impaired memory function (p < 0.05 vs. scrambled control, t-test). 
B. A microRNA-181a-5p inhibitor oligonucleotide was injected in into the dorsal hippocampus of aged mice (16 
month of age, 16Mo). A scramble control oligonucleotide injected into the hippocampus of 3- and 16-months old 
mice was used as control. ANOVA revealed a significant difference amongst groups (p = 0.04). While freezing 
behavior was impaired when comparing scramble-injected 3 vs. 16 months old mice (p = 0.02), no such difference 
was observed when the group of 16 months old mice that received microRNA-181a-5p inhibitor were compared 
to the scramble-injected 3 months old mice (p = 0.6). Error bars indicate SEM. 
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Fig S9. mciroRNA-181 is highly conserved across species. 
Left panel: Multiple sequence alignment of microRNA-181a-5p mature sequences from different species. 
microRNA-181a-5p seed sequence is conserved across different species. Right panel: microRNA-181a-5p 
expression across different human tissues based on miRMine Database. Note that microRNA-181a-5p is highest 
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Mounting evidence suggests the co-occurrence of cardiac failure and dementia. The 
mechanisms that drive cardiac failure-induced cognitive decline and thereby increase the risk 
for dementia remain, however, largely unexplored. Moreover, therapeutic intervention for 
managing cognitive impairment in heart failure patients is missing. In this study, we analyze 
the neuronal function and memory performance in a mouse model for cardiac hypertrophy. We 
observed that mice in which cardiac-specific CamkIIδc is overexpressed in the heart exhibit 
massive alterations in hippocampal gene-expression that resemble changes observed in 
neurodegenerative diseases. Up-regulated genes represent endoplasmic reticulum-stress (ER)-
stress, while down-regulated genes are linked to neuronal function, histone-methylation, and 
synaptic plasticity. In line with these data, CamkIIδc mutant mice exhibit memory impairment 
that was associated with reduced neuronal histone 3 lysine 4 tri-methylation (H3K4me3), a key 
euchromatin mark implicated with active gene expression. Oral administration of Vorinostat 
(SAHA), an epigenetic drug that promotes euchromatin formation, was able to reinstate 
memory function in CamkIIδc mutant mice via the elevation of H3K4me3-related re-
expression of synaptic plasticity genes. In addition, SAHA regulated a brain-specific 
microRNA-network that counteracted ER-stress-related gene-expression. Our study provides 
the first insight into the molecular processes that influence brain function as a result of cardiac 
diseases and suggests that epigenetic strategies could be suitable to restore cognitive function 
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Introduction 
 
Heart failure (HF) and dementia share similar risk factors including vascular factors, age, lack 
of education, and gender1-3 . Reduced cardiac contractility and dysfunctions in cardiac 
perfusion are functional characteristics of heart failure patients. Studies investigating brain 
anatomy in heart failure patients reported reduced cerebral blood flow in HF brains compared 
to that of healthy controls4. Regional hypoperfusion due to the failing heart may result in 
functional and structural alterations of the brain. In a recent study, hypoperfusion in both 
prefrontal cortex and hippocampus along with other regions has been reported in HF patients4. 
Moreover, cerebral structural alterations have been described in both white5 and gray matter6 
as well as in different brain regions, including the cortex and hippocampus. Furthermore, 
another study reported reduced regional cortical thickness in HF patients that may be attributed 
to the loss of different brain cells6. Concordantly, recent functional imaging data revealed tissue 
loss in frontal cortex7 and hippocampus8 of HF patients. 
Since these are brain regions of critical functions, hippocampus in particular, and are inherently 
linked to learning and memory, structural damage in these regions is likely to affect cognition. 
In agreement with this, mounting evidence shows that heart failure can be associated with 
cognitive impairment1,9,10. A high prevalence of early-onset cognitive deficits ranging between 
25%-75% has been reported in patients with failing heart11-14. Despite such high prevalence, 
(i) the underlying molecular changes occurring in the brain as a result of heart failure are poorly 
understood and (ii) therapeutic strategies for the management of cognitive impairment in HF 
patients are missing. 
 
A recent study pointed out a possible association between improvements in cardiovascular 
health with a lower incidence of dementia1. However, drugs (e.g., β -blockers, digitalis, 
aldosterone antagonists) that have been used in HF patients lack evidence for improving 
cognition15-17. Although ACE inhibitors showed some potentials to benefit cognition in HF18, 
contrasting results from other study demonstrate its association with an increased incidence of 
Alzheimer´s disease19. Concerns regarding other novel agent such Subcubitril/Valsartan and 
its potential to promote Alzheimer´s disease is not yet eliminated20,21. Also, other heart failure 
therapies e.g. left ventricular assist devise (LVAD), veno-arterial extracorporeal membrane 
oxygenation (VA-ECMO) have been associated with cognitive impairment13.  Therefore, 
proven therapeutic options to ameliorate cognitive impairment in HF are absent, which is most 
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likely due to the fact that the mechanistic insight that underlies the cognitive changes following 
reduced perfusion in the brain is missing. Consequently, the European Society of Cardiology 
(ESC) recently recommend joint efforts of experts from cardiology and dementia research to 
investigate therapeutic interventional options for managing cognitive impairment in subjects 
with cardiac failure22.  
 
In this study, we employ a mouse model of cardiac hypertrophy and heart failure to study the 
mechanisms that lead to altered brain function and memory impairment. Our results showed 
that cardiac hypertrophy leads to massive changes in hippocampal gene expression linked to 
increased stress responses (e.g., oxidative, endoplasmic), protein misfolding, autophagy, and 
decreased neuronal plasticity. These changes in gene expression are partly linked to epigenetic 
modifications and a loss of euchromatin. In line with this, HF mice exhibited cognitive deficits. 
Aberrant gene expression and memory impairment were ameliorated via the oral treatment of 
Vorinostat (SAHA), an epigenetic drug that promotes euchromatin formation. SAHA also 
induced a microRNA network that counteracted the detrimental expression of ER-stress related 
genes. To the best of our knowledge, this is the first study that elucidates the molecular changes 
in the hippocampus in the context of cardiac hypertrophy and heart failure. Moreover, we 
propose that epigenetic therapeutic intervention may help in clinical settings to improve 
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Results 
CamkIIδc overexpression in heart leads to brain gene expression changes 
similar to neurodegenerative diseases  
 
Since cardiovascular risk factors can negatively influence overall brain health23,24, we used a 
heart failure (HF) transgenic mouse model to investigate the effect of faulty heart in shaping 
brain functions. Transgenic mice were bred according to previous study25 and they 
overexpressed CamkIIδc exclusively in the heart owing to alpha-MHC promoter upstream of 
its transgene (Fig 1A). At the age of 3 months, these mice displayed shrinkage of the lumen 
volume (Fig 1B), increased systolic as well as diastolic diameter (Fig 1C) in the left ventricle 
and lower ejection fraction rate (Fig 1D) compared to age-matched littermate controls. These 
data imply that compared to controls, normal cardiac function is substantially reduced in 
transgenic mice. Although transgenic mice displayed similar body weight (Fig 1E), their heart 
weight (Fig 1F) was substantially increased compared to controls. Consistently, heart to body 
weight (Fig 1G) ratio and particularly the weight of the left ventricle in the heart (Fig 1H) were 
significantly higher in transgenic mice. However, we failed to observe significant differences 
in terms of tibia length (Fig S1A), lung to body weight (Fig S1B) and lung weight/tibia length 
ratio (Fig S1C) between groups.  Hypertrophic heart and reduced cardiac functions as observed 
in this transgenic mice corroborate previous findings from other studies25,26. CamkIIδc 
overexpression dependent prolonged ryanodine receptor (Ryr2) activation followed by 
sarcoplasmic reticulum calcium leakage underpin reduced contractile function observed in 
these transgenic mice25,26. Recent studies have shown that cardiac disruptions in ryanodine 
receptors and defective Ca2+ signaling in the myocardium can exacerbate endoplasmic stress, 
protein misfolding, oxidative response and autophagy in the hearts of cardiac failure patients27. 
Recent attempts to understand detailed genetic interactions in heart failure have led studies 
investigating cardiac transcriptomics from healthy and disease conditions28-30. We analyzed 
one of these data30 and found that indeed, heart failure leads to significant dysregulations of 
cardiac transcriptomics (Supplementary Table 1a, Fig S1D) compared to those of healthy 
controls. Interestingly, down-regulated genes could be involved in different biological and 
molecular processes, including heart contraction and heart process as expected (Fig S1E). 
Moreover, they are also likely to contribute to protein folding and RNA splicing (Fig S1E, 
Supplementary Table 1b).  
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Fig 1. Mice overexpressing CamkIIδc display ER stress response in the molecular level.  
A) scheme of mice overexpressing CamkIIδc in the hearts of the transgenic mice. B) Immunostaining for the left 
ventricle tissue sections and C) M-mode images from left ventricle from wild-type and transgenic mice. ESD: 
Left ventricle end systolic diameter, EDD: Left ventricle diastolic diameter. D) Ejection fraction is significantly 
decreased to ~50% in transgenic mice (n = 8) compared to control mice (n = 5). (E) CamkIIδc transgenic mice 
have similar body weight to transgenic control. Weight of heart (F), heart to body (G) and left ventricle (H) are 
increased in transgenic mice (n = 8) compared to control (n =5). (I) Scheme of the sequencing experiment.   
Principle component analysis (PCA) plot of transcriptomic data shows that transgenic mice (n =6) are different 
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from control mice (n=5) in terms of gene expression. First principle component (PC1) can explain 42% of the 
variation between the two groups. (J) Volcano plot showing differentially expressed genes (FDR<0.05). Red color 
indicates upregulation, while blue represents the downregulation of transcripts. Heatmap showing the number of 
genes deregulated in transgenic mice compared to age-matched littermate controls. K) Hypergeometric overlap 
analysis taking genes deregulated in transgenic mice and comparing it to genes uniquely expressed in neuron, 
astrocytes, and microglia. Color represents the fold enrichment. Values in the box (top to bottom) represent fold 
enrichment, hypergeometric overlap p-value and asterisks based on the significance level L) Top GO biological 
processes after removing redundant GO terms using Rivago, are summarized in a dot plot. M) qPCR quantification 
of Bcap31, Fez1, Fez2 in control and transgenic mice (n = 5 each group). Quantitative PCR for Kmt2a between 
transgenic (n = 4) and littermate controls (n = 5). *p<0.05, Unpaired t-test; two-tailed. Data is normalized to Hprt1 
expression. N) Overlap between deregulated genes in CamkIIδc transgenic mice with those from aging, AD, 
FTLD, and PD datasets. #p=0.08, *p<0.05, **p<0.01, ***p<0.001. Unpaired t-test; two-tailed. Error bars indicate 
mean ± sem 
 
 
We asked whether cardiac dysfunctions could affect similar molecular processes in brain. To 
investigate this question, we micro-dissected the CA1 hippocampal sub-region from 3 months 
old transgenic and control mice and subjected its RNA to bulk RNA sequencing (Fig 1I). 
Interestingly, the first principle component showed distinct transcriptomic profiles between the 
two groups (Fig 1I). Differential expression analysis revealed 3794 genes as significantly 
deregulated between groups (FDR <0.05). Of these, 1780 genes were up-regulated whereas 
2014 genes were down-regulated in transgenic mice when compared to the control group (Fig. 
1J, S1E, Supplementary Table 2a). Since CamkIIδ expression in brain (FDR 0.52, 
Supplementary Table 3) did not change between groups, the observed changes in brain gene 
expression as observed can be attributed to CamkIIδc overexpression in heart and associated 
hypoperfusion.  
 
A previous study reported that the neuro-vascular unit in the brain, composed of different cell 
types including but not limited to neurons, microglia, and astrocytes, regulates vascular 
recruitment in response to local oxygen demands and functional activity in brain31. We 
reasoned that these different cell types in the brain may respond to hypoperfusion induced 
molecular changes differently. In fact, we and others have shown that peripheral insults can 
lead to distinct transcriptomic changes in different brain cell types 32-34 to shape brain function. 
To determine whether the deregulated genes in CamkIIδc mice would reflect any cell type-
specific enrichment in brain, we analyzed deposited sequencing data from neuron, microglia, 
and astrocytes35. Hypergeometric test revealed that up-regulated genes overlapped 
significantly with astrocytes and neurons (Fig 1K).  In contrast, down-regulated genes showed 
significant enrichment only in neuron (Fig 1K).  
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Investigating the functional relevance of these deregulated genes, we found the down-regulated 
genes are likely to be involved in mRNA processing (Fig 1L, Supplementary Table 2b, 2c), 
especially RNA splicing and protein folding. The downregulation of neuron-specific splicing 
factors in CamkIIδc transgenic mice (Fig S1G) may hint at its potential causal effect on reduced 
splicing. Of note, similar biological processes are down-regulated in the hearts of cardiac 
failure patients (Fig S1E). These data suggest that homologous molecular responses could 
interplay between the heart and brain in HF model. In addition, genes related to cognition and 
methylation processes are down-regulated in transgenic mice (Fig 1L). In agreement with this, 
insulin signaling, mTOR signaling, AMPK signaling, and MAPK signaling pathways related 
to cognition36-39 are down-regulated as well in transgenic mice (Fig S1H).  
 
On the contrary, up-regulated genes are likely to be autophagy, apoptotic signaling, and 
endoplasmic reticulum (ER) stress-related (Fig. 1L, supplementary Table 2b, 2c). qPCR data 
confirmed the increased expression of a few selected ER stress related genes (Fez1, Fez2, 
Bcap31) as well as the decline of Kmt2a expression, a writer of histone modification, in 
transgenic mice compared to controls (Fig 1M). A previous study has showed that loss of 
Kmt2a in the brain leads to cognitive impairment40. Increased unfolded protein and ER stress 
response, along with decreased cognition, have been previously reported in various 
neurological diseases41. Therefore, we asked whether the gene expression changes as observed 
in this study would overlap with those of other neurodegenerative diseases. To this end, we 
retrieved multiple datasets related to aging42, analyses of Alzheimer´s (AD)43, Parkinson (PD)44 
and Fronto-temporal dementia (FTLD)45 disease-specific differentially expressed genes 
compared to corresponding controls. Subsequently, we performed gene enrichment analyses 
of de-regulated genes from CamkIIδc transgenic mice and deregulated genes from each of the 
aforementioned diseases. In fact, we investigated up- and down-regulated genes separately. 
Interestingly, up-regulated genes in CamkIIδc transgenic mice representing stress responses 
(Fig 1L) significantly overlap with up-regulated genes in all the above diseases with exception 
in PD (Fig 1N). On other hand, down-regulated genes representing cognition and splicing are 
overlapped with those from advanced aging, AD, FTLD, and also PD (Fig 1N). These data 
suggest that, CamkIIδc transgene overexpression can contribute to upregulation of stress-
responsive genes along with the downregulation of cognition related genes in the mouse brain 
akin to neurodegenerative diseases. 
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Heart failure model mice display cognitive impairment at an early age  
 
Given that we investigated the brain transcriptomic profile of HF mice at an early age (3 
months), observing similar gene profile changes associated with diseases characterized by 
aging and memory loss was intriguing and promoted us to investigate cognition in the 
transgenic mice. To this end, we employed behavioral experiments that assay spatial reference 
memory in mice (Fig 2A).  Before cognitive performance evaluation, first, we tested whether 
anxiety-related responses would vary between groups. In this regard, 3 months old transgenic 
and control mice were subjected to the open field test (Fig 2A). Our results showed that both 
transgenic (n = 16) and control (n = 13) mice spent a similar percentage of time in the middle 
region of the test field, traveled similar paths and moved at almost identical speeds (Fig 2B). 
These data demonstrated that cognitive performance would be unlikely to be affected by a basal 
level difference in anxiety. Subsequently, mice were subjected to the Barnes maze, a spatial 
navigation learning test that evaluates cognitive performance in mice by utilizing 
environmental cues and an escape hole (Fig S2). TWO-way ANOVA analyses revealed that 
transgenic mice required significantly more time to find an escape hole compared to littermate 
controls (Fig 2C). A further detailed analysis considering head angles and trajectories (Fig 
S2B) employed by mice during learning of the task showed that transgenic mice used strategies 
that are less hippocampal-dependent (direct, short and long chaining strategic approach) 
compared to controls (Fig. 2D). Consistently, cumulative strategy scores calculated based on 
hippocampal-dependent strategies (see methods for details) revealed a significant difference 
between groups (Fig 2E), confirming that transgenic mice were poor performers in training 
trials. Next, a memory retrieval test was performed by closing the escape hole. During the 
retrieval phase, visits to the escape hole were enumerated. Transgenic mice visited the target 
hole less frequently than did controls (Fig S2F), suggesting an impairment of memory retrieval 
in transgenic mice (Fig 2F).   
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Fig 2. Behavior data at 3 months of age.  
A) Behavioral tests (e.g. open field, Barnes maze) were performed with transgenic (n = 16) and control mice (n = 
13) at 3 months of age. B) Percentage of time spent in middle region (left panel), traveling path (middle panel) 
and speed (right panel) during test in both groups (two-tailed, unpaired t-test) C) Escape latency in control and 
transgenic mice (two-way ANOVA, *p<0.05) D) Different strategies based on mice trajectories across trials. Each 
strategy is labelled with a unique color. E) Cumulative strategy scores across training trials and F) number of 
visits in escape hole during probe test (right panel) [two-tailed, unpaired t-test, *p<0.05). Error bar indicates mean 
± sem   
 
 
 In summary, these data demonstrate that CamkIIδc overexpression-based heart failure model 
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Histone modifications may underpin cognitive deficits  
 
Since our functional enrichment results based on down-regulated genes previously pointed to 
downregulation of methylation in transgenic mice (Fig 1L), we reasoned that epigenetic 
changes might underpin the cognitive deficits (Fig 2) in transgenic mice. To gain more 
confidence in this, we decided to compare deregulated genes from our transgenic mice with 
those from other studies wherein different histone modifier enzymes were genetically 
manipulated, and their effects on cognition was examined. Thus, we retrieved and analyzed 
RNA-seq data from Kmt2a46, Kmt2b40, and Kat2a47 knockout experiments. Of note, 
significantly deregulated genes (FDR <0.05) were determined from comparisons with 
littermate controls from each study40,46,47. Cognition was impaired in all of these transgenic 
mice, mainly due to the downregulation of synaptic plasticity-related genes of neurons40,46,47 
(Supplementary Table 3a-c). Interestingly, both up- and down-regulated genes overlap with 
corresponding those from kmt2a knockout only (Fig 3A). Moreover, overlap between down-
regulated genes from our transgenic mice and those from Kmt2a knockout experiments (5.1 
fold, FDR 1.45e-73) outnumbers other enrichments (Fig 3A). Surprisingly, no significant 
enrichment was observed with genes deregulated in Kmt2b knockout mice (Fig 3A). These 
data suggest that changes in gene expression in our heart failure model could be, at least in 
part, dependent on reduced Kmt2a level. Indeed, we confirmed a substantial reduction of 
Kmt2a (Fig 2B) expression in transgenic mice compared to littermate controls (Fig 2B) through 
quantitative PCR as previously mentioned.  Reduced levels of Kmt2a, a writer of H3K4me348, 
are likely to decrease global H3K4me3 as it has been shown in previous studies46,49. Therefore, 
we decided to assess the functional influence of reduced Kmt2a on H3K4me3 levels. Of note, 
H3K4me3 is enriched globally at promoters of transcriptionally active genes50,51 and reduced 
H3K4me3 depositions at genes promoter negatively affect genes transcription52. We 
hypothesized that there could be a causal relationship between the downregulation of neuronal 
enriched genes and H3K4me3 marks at their promoters.  To test this, we devised immuno-
precipitation for H3K4me3 from sorted neuronal nuclei and performed high throughput Chip 
sequencing as outlined in Fig 2B. We investigated the level of H3K4me3 at the promoter of 
down-regulated genes by aligning Chip-seq reads to transcription start sites (TSSs) of those 
genes. Since lengths of gene promoters vary in genome53, we examined 2 kb up- and down-
stream of transcription start site (TSS) as a proxy of gene promoters. In wild type mice for the 
down-regulated genes, we observed that the level of H3K4me3 peaks slightly downstream of 
TSSs and gradually declines over the first 1kb (Fig 3C).  Previous studies have found a similar 
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pattern of H3K4me3 at TSS50.  Interestingly, down-regulated genes have substantially reduced 
H3K4me3 level at their promoters (TSS ± 2 kb (Fig 3C) in transgenic mice compared to those 
from littermate controls, suggesting a potential role of H3k4me3 in dampening gene 
expression. 
  
In further comprehensive analyses, a total of 138026 H3K4me3 narrow peaks were detected in 
both groups, of which 8506 peaks were up-regulated while 7741 peaks were down-regulated 
in transgenic mice compared to littermate controls (Fig 3D). Significantly deregulated peaks 
are visualized in Fig 3D. 25% of these deregulated peaks were annotated to be at the promoters 
(TSS ± 2kb) of genes, while most of the other peaks fall into distal intergenic regions and other 
non-coding regions (Fig 3E). Genes with H3K4me3 peaks are likely to be involved in RNA 
metabolism and protein-protein interaction at synapses (Fig 3F). Next, we studied genes 
characterized by (i) H3K4me3 peaks at the promoters (TSS ± 2 kb) and (ii) showed significant 
transcriptional deregulation (FDR <0.05) in transgenic mice compared to controls. We thus 
limited our further analyses to 2293 genes that met these criteria and  pairwise correlation 
analysis between RNA-seq and Chip-seq profile for these genes from the same set of samples 
was subsequently performed.  
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Fig 3. H3K4me3 profile in transgenic and control mice  
A) Hypergeometric overlap test among deregulated genes from this study, and altered genes from studies 
investigating Kat2a, Kmt2a, and Kmt2b knockouts in mice. Down-regulated genes from this study show 
considerably higher overlap with down-regulated genes from Kat2a and Kmt2a knockout mice B) Scheme of 
FACS from the mouse hippocampus (CA1 + CA3). C) NGS plot for down-regulated genes showing H3K4me3 
peaks sharply declined at the promoter (TSS ± 2 kb) of the down-regulated genes. D) Heatmap showing number 
of deregulated peaks (FDR < 0.05) and MA plot showing the distribution of up- and down-regulated peaks in 
transgenic mice compared to controls. X axis represents mean peak intensities (log2 scale) and Y axis shows fold 
change (log2). E) Pie-chart showing annotated peaks across different regions in the mouse genome (mm10) F) 
Annotated genes of deregulated peaks could contribute to RNA metabolism and protein-protein interactions at 
synapses. G) Left plot showing correlation between H3K4me3 peaks and RNA-seq expression for significantly 
deregulated genes. Based on correlation two clusters are presented.  Correlation patterns of neuronal and glial cell 
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type enriched clusters are represented as thick red line, dashed blue line respectively. Gene expression (middle 
panel) for corresponding genes are plotted for both control and transgenic groups. Color bars represent annotation 
for correlation co-efficient, RNA expression, and genotypes. H) Bar plot showing gene ontology of three clusters. 
X-axis represents FDR (-log10 scaled) while Y-axis represents the gene ontology biological processes. 
 
 
We found two significantly correlated clusters based on this analysis (Fig 3G, Supplementary 
Table 4). One cluster representing down-regulated genes in transgenic mice had a positive 
correlation with the H3K4me3 profile. Since we initially observed down-regulated genes 
highly overlap with neuronal genes, we named this cluster as neuron-enriched cluster.  Of note, 
we initially observed reduced H3K4me3 globally for down-regulated genes (Fig 3C). 
Therefore, the downregulation of neuron enriched cluster and its positive correlation with 
down-regulated H3K4me3 marks at their promoter further confirms a causal gene-epigenetic 
relationship at single-gene resolution (Fig 3G). The other cluster instead showed a positive 
correlation between RNA-seq and H3K4me3. Gene sets of this cluster showed up-regulation 
in transgenic mice and thus was named glia enriched cluster. The negative correlation between 
gene expression and H3K4me3 peaks at their promoter suggesting that other kmt2a 
independent epigenetic modification and/or non-histone transcription factors could mediate the 
overexpression of this cluster. Given that we investigated the H3K4me3 profile in the neurons, 
the upregulation of the gene cluster representing glial cell-type could be due to other possible 
epigenetic modifications. 
 
Gene ontology analysis revealed that neuron-enriched cluster is likely to be involved in RNA 
splicing and protein folding (Fig 3H, Supplementary Table 4). Moreover, neuron enriched 
cluster gene sets are likely to be also involved in the post-synaptic organization and dendritic 
spines density (Supplementary Table 4). Therefore, H3K4me3 dependent reduction of these 
genes’ expression may negatively affect synaptic plasticity, leading to poor cognitive 
performance in transgenic mice. In support of this hypothesis, the previous study showed that 
loss of Kmt2a results in decrease of synaptic plasticity-related genes, an outcome that has been 
linked to observed cognitive deficits and attributed to a global decline in H3K4me3 profile46. 
Glia enriched cluster is likely to be involved in increased autophagy, ER and oxidative stress 
response, and negative regulation of neuronal functions (Fig 3H, Supplementary Table 4).  In 
summary, both H3K4me3 linked reduction in RNA splicing and synaptic plasticity, as well as 
H3K4me3 independent exacerbation of ER/oxidative stress responses conjointly may have 
precipitated cognitive deficits in our heart failure animal model. 
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SAHA rescues early age cognitive deficits in CamkIIδc transgenic mice 
 
Despite early cognitive deficits in transgenic mice, we reasoned that early therapeutic 
interventions might ameliorate memory impairments. In this study, we have found evidence 
that reduction of H3K4me3 at the promoters of neuronal enriched and cognition related genes 
could be the potential underlying mechanism of cognitive deficits in the heart failure animal 
model. Accordingly, we asked whether we could restitute memory in these mice, through 
genome-wide increased distribution of H3K4me3. We envisioned to accomplish this through 
histone deacetylase inhibitors. Histone deacetylase (HDAC) inhibitors are “chromatin 
openers” that favors gene expression and have been linked with memory improvement in 
cognitively impaired animal models42,54,55. Previous studies have shown that HDAC inhibitors 
could increase both histone actelylation and methylation levels56,57. We reasoned that 
Vorinostat (SAHA) could be a right HDAC inhibitor choice due to its effect of restoring the 
transcriptomic profile and potentially rescuing cognitive deficits in memory-impaired mice42. 
As the first step towards SAHA mediated interventions, we investigated SAHA´s potential to 
increase H3K4me3 in neurons. Western blots revealed that SAHA not only increased H3K9ac 
intensity as expected, but also substantially increased H3K4me3 intensity after 1 hour of 
treatment in primary neuronal culture (Fig S3A). Since H3K9ac and H3K4me3 marks are 
similar in terms of genome-wide distribution and functionally related52,58, such an observation 
was of no surprise. Moreover, SAHA´s potential to increase both H3K9ac and H3K4me3 level 
has been reported in previous studies, albeit in different cell types56,57. Concordantly, Chip-seq 
based analysis revealed that SAHA could induce genome-wide changes in both H3K4me3 and 
H3K9ac profile57.  
 
Increased histone modifications and induction of a more relaxed chromatin state following 
SAHA treatment are likely to alter gene expression pattern. Therefore, we decided to 
investigate SAHA´s potential to change gene expression patterns as an output of these 
epigenetic changes. In our previous study, we showed that cognitively impaired old mice 
display substantial changes in gene expression compared to cognitively healthy young mice42. 
We have observed similar gene expression changes in CamkIIδc transgenic mice compared to 
controls (both up- and down-regulated genes) as shown in Fig S3B with a highly significant 
overlap between two data (see also Fig 1N). Benito et al42 showed that oral treatment of SAHA 
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in old mice could not only induce a transcriptional profile similar to that of young mice but 
also lead to cognitive improvement. Comparative analysis with data from our heart failure 
model and previous study42 revealed that up- and down-regulated genes from CamkIIδc mice 
significantly overlapped with down- and up-regulated genes respectively in old SAHA vs. Old 
vehicle42, highlighting SAHA´s potential to target similar gene sets and to reverse  their 
expression patterns in CamkIIδc transgenic mice (Fig S3B).  
 
 
Both of these observations prompted us to examine the effects of SAHA directly on cognitive 
deficits. Therefore, transgenic mice were given Vorinostat (SAHA) (0.67 g/L) in drinking 
water for 1 month from two months of age (TS). Another group of transgenic mice (TV) and 
additional littermate controls (WV) were given only vehicle in drinking water for an equal 
duration (Fig 4A). Previous studies reported that SAHA could cross blood-brain barrier59-62, 
have no negative influence on liver, and show limited effects on transcriptomics of cognitively 
healthy mice at the given dose42. After 1 month of treatment at the age of 3 months, mice were 
subjected to a similar battery of behavioral tests as previously mentioned. In the open field test, 
mice from all groups spent a similar time in the middle region of the field, traveled similar 
paths and displayed similar speeds (Fig 4B). These results suggest that there was no base level 
difference in terms of anxiety among groups as it was observed previously (see Fig 2). Next, 
we performed Barnes Maze to evaluate spatial learning and memory retrieval in mice. 
Transgenic mice with vehicle (TV) exhibited higher escape latencies to find the escape hole 
compared to littermate controls (WV), akin to previous observations (see Fig 2). However, 
transgenic mice treated with SAHA (TS) performed similarly to littermate controls (WV) (Fig 
4C). Increased escape latency in TV may be attributed to a decline 
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Fig 4. A behavioral experiment in SAHA/vehicle treated mice  
A) A schematic outline showing the experimental settings. One group of transgenic mice was given SAHA (TS) 
while other group was given vehicle (TV) and their behavioral performance were compared to that of control mice 
treated with vehicle (WV). Drug/vehicle treatment was conducted for 4 weeks (n = 10 each group). B) Percentage 
of time in middle regions (left panel), path traveled (middle panel), and speed (right panel) are shown from open 
field test (one-way ANOVA). C. Escape latency to target hole in three different groups over seven training trials 
(Two-way ANOVA, **p<0.01). D) Area curve plot for different strategies that mice employed during trials. 
Colors represent strategy. E) cumulative hippocampal-dependent strategy scores from training trials and F) 
number of target visits during probe test among groups (One-way ANOVA, *p<0.05, **p<0.01). Error bars 
indicate mean ± sem.  
 
 
in direct, short and long chaining strategies, particularly at the 7th trial (Fig 4D). Consistently, 
a cumulative score calculated based on these strategies (see methods for details) showed 
significant cognitive performance decline in TV mice across trials compared to WV mice, 
while in TS group the learning ability was partially rescued (Fig 4E). A memory recall test 
during the probe test confirmed our previous observation (Fig 2F) of substantial memory 
decline in transgenic mice. However, TS mice displayed memory reinstatement due to SAHA 
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treatment (Fig 4F). Based on these data, we conclude that oral treatment of SAHA in transgenic 
mice can ameliorate cognitive deficits (Fig 4). 
 
 
SAHA may restore transcriptomic changes in transgenic mice 
 
Based on our previous analysis (Fig S3B), we hypothesized that SAHA mediated cognitive 
rescue as observed in transgenic mice could be due to the reinstatement of the brain 
transcriptomic profile in transgenic mice. Therefore, we investigated changes in gene 
expression as a proxy of potential genome-wide increased distribution of H3K4me3 mediated 
by SAHA. To this end, we sacrificed mice and micro-dissected CA1 region from all the three 
experimental groups; wild type vehicle (WV), transgenic vehicle (TV) and transgenic SAHA 
(TS). RNA was then isolated, and RNA-seq was performed (Fig 5A). Phenotyping of these 
mice showed that body weight and lung weight were not affected in any of the experimental 
groups (Fig S5B-C). Similar results were observed for the whole heart and left ventricle (Fig 
S5D, Fig S5E). After adjusting for both technical and biological covariates, our RNA-seq data 
analysis revealed major deregulation of mRNAs in the transgenic vehicle group compared to 
littermate controls (Fig S4A). This result supports previous observation (Fig 1J), and this 
consistency was further reflected in the functional analysis performed using deregulated genes 
(Fig 5B). RNA splicing and protein folding were down-regulated while increased unfolded 
protein response, oxidative and ER stress response, autophagy and neuronal death were 
observed in TV mice. Interestingly, SAHA could partially reinstate gene expression changes 
in TS mice (Fig S4B), an effect which was observed for both up (38%) and down-regulated 
(39%) genes (Fig S4B). Concordantly, SAHA could reverse deregulated concerned biological 
processes in transgenic mice (Fig 5B) and was likely to increase non-coding RNA mediated 
regulations (Fig 5B). We wanted to test whether SAHA could rectify splicing in TS group and 
reasoned that differential exon usage would be a proxy to different splicing events, and 
informing us of any bias to use one exon over another. Therefore, we performed differential 
exon usage in TV and TS, both as compared to WV. SAHA led to a dramatic increase of 
differential exon usage in TS vs. WV condition compared to TV vs. WV (Fig S4C). In support 
of this, similar SAHA mediated increased differential exon usage has been illustrated in a 
previous study42 
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To gain better insights about molecular mechanisms that underpin this SAHA mediated 
cognitive rescue, we further investigated the RNA-seq data in greater details and asked how 
the expression of different co-expressed clusters would change among groups. Recent studies 
showed that co-expression of regulatory clusters could point to key mechanisms underlying 
disease conditions63-66.  We aimed to find hub genes of the interesting clusters and hypothesized 
that these hub genes could be under the regulation of other epigenetic mechanisms e.g., through 
microRNAs (Fig 5C). The above hypothesis was based on the previous observation that, SAHA 
could increase non-coding RNA regulations (Fig 5B). To this end, we performed Weighted 
Gene Co-expression Analysis67 and found 14 different clusters (Fig 5D-E, Fig S4E). We 
limited our analysis to modules that show differential expression among groups and found two 
such modules. The first module, RNA module 1 module, displayed reduced expression in TV 
(Fig 5D) compared to WV but partial rescue in TS group (Fig 5D).  Gene ontology analysis 
indicated that the gene members of RNA module 1 are likely to be involved in action potential, 
cognition, and learning memory (Fig 5E, Supplementary Table 5). Therefore, RNA module 
1 cluster represents a gene cluster linked to cognition. Regulatory network of this cluster is 
illustrated by hub genes (Fig 5E) and evidence that most of these genes are key players in 
context of learning and memory are summarized in Supplementary Table 6. Downregulation 
of these memory-related hub genes in TV group may contribute to cognitive decline and 
SAHA´s potential to modulate their expression levels make it an ideal candidate for therapeutic 
interventions in memory disorders. In contrast, expression of the second module, RNA module 
2 module, increased in transgenic vehicle (TV) group compared to littermate controls (WV) 
(Fig 5F), but partially normalized in transgenic + SAHA group (TS) (Fig 5F). RNA module 2 
cluster member genes significantly overlap with oxidative stress response, autophagy and 
different stress-induced kinase response biological processes (Fig 5G, Supplementary Table 
5). Since our gene ontology analyses consistently point towards increased oxidative response, 
ER stress, and autophagy in addition to reduced cognition related processes, we decided to 
investigate the effects of these different stress conditions on gene expression. We examined 
whether hypoxic and ER stress conditions could induce similar gene expression changes as 
observed in heart failure mice.  To this end, first we compared the deregulated genes in 
transgenic vehicle (TV) group with genes deregulated in hypoxic condition from a recent 
study68. Pasca et al.68 showed that hypoxia induces distinctive expression changes in neurons 
after 24 and 48 hours.   
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Fig 5. Orally given SAHA rescues cognitive performance through possible combinatorial effects.  
A) Scheme of RNA-seq from studied experimental groups (n = 10 each group). TS = Transgenic mice + SAHA; 
TV = transgenic mice + vehicle; WV = control mice + vehicle.  B) Featured biological processes from gene 
ontology analysis of the deregulated genes is summarized in dot-plot. C) Outline of a gene co-expression-based 
workflow to investigate underlying molecular mechanisms. D) Expression of RNA module 1 among the three 
groups. *p<0.05, Kruskal Wallis test E) (top panel) Gene ontology analysis of gene members from RNA module 
1. (bottom panel) Network representing top 30 hub genes of the gene network based on RNA module 1. Gene 
network was visualized in VisANT 5.0. F) RNA module 2 and its expression among three groups *p<0.05, 
Kruskal Wallis test G) (top panel) functional annotations of genes from RNA module 2. (bottom panel) top hub 
genes (n =30) in gene correlation network of RNA module 2. H) Heatmap summarizing results from 
hypergeometric tests for deregulated genes in transgenic mice with hypoxic and tunicamycin induced ER stress 
conditions. Up and down-regulated genes (FDR<0.05) were determined by comparing with corresponding 
controls. Fold enrichment cutoff: 1.2 and enrichment significance cutoff: FDR < 0.001. Color intensity represents 
fold enrichment.  
 
 
We found that the up-regulated genes in our transgenic vehicle (TV) group overlap 
significantly with those of 24-hour and 48-hour long hypoxic treatment (Fig 5G). Moreover, 
up-regulated genes significantly overlap with RNA module 2 modules as well (Fig 5F, 5G), 
confirming that these changes are stress responsive. Next, we modeled ER stress in a primary 
neuronal culture system (Fig S5A) through a 6-hour long tunicamycin treatment. Induction of 
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ER stress using tunicamycin has been described elsewhere69-72. The genes up-regulated after 
tunicamycin treatment compared to vehicle only controls showed significant overlap with up-
regulated genes in transgenic mice treated with vehicle (TV) compared to littermate controls 
(WV). In summary, gene expression changes in our transgenic mice overlap with those from 
increased hypoxic and ER stress responses. So far, biological process analysis revealed that 
SAHA is likely to reduce these stress responses (Fig 5B, 5F). This was confirmed in our cell 
culture model, as SAHA pretreated neurons showed a weaker ER stress response compared to 
neurons treated with only tunicamycin (Fig S5B). Further confirmation came from qPCR 
experiments performed for selected ER stress responsive genes in mice. Increased expression 
of ER stress responsive genes (e.g. Bcap31, Fez2) were noted in TV mice, but their expression 
was normalized in transgenic mice treated with SAHA (TS) (Fig S5C).   Therefore, data from 
cells and animal model show that SAHA can restore transcriptomic homeostasis and have 
protective role against oxidative and endoplasmic stress responses. 
 
 
microRNAs may play a critical role in compensation of stress response 
 
This observation led us to ask our next question of how SAHA, a histone deacetylase inhibitor, 
that generally opens up chromatin and facilitates increased gene expressions could reduce 
expression of stress-related genes. To explain this seemingly somewhat inverse relation 
between SAHA and gene expression, we reasoned that SAHA driven increased microRNA 
expression might play a key role in regulating in ER and oxidative stress responses.  
 
To investigate this hypothesis, we carried out small RNA sequencing from TV, WV, and TS 
groups (Fig 6A). Similar to RNA-seq, we performed weighted co-expression analysis on all 
samples (Fig 6B). Our analysis revealed five different clusters based on co-expression patterns 
(Fig 6C, Fig S6D) and we evaluated their expression changes among groups using eigenvalue. 
We limited our analysis to two clusters that displayed differential expression among groups 
(Supplementary Table 7). Expression of the first cluster, microRNA module 1, was notably 
up-regulated in TV but fully rescued in TS (Fig 6C). In contrast, microRNA module 2 showed 
reduced expression in the TV group. Interestingly, oral administration of SAHA could also 
fully compensate this change in TS group (Fig 6D). Since microRNAs are known for silencing 
gene expression, we hypothesized that the increased expression of microRNA module 2 in 
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transgenic mice following SAHA treatment (compared to transgenic mice with vehicle) might 
negatively affect mRNAs involved in stress responses. If this hypothesis holds true, we 
expected a negative correlation pattern between increased microRNA and decreased mRNA 
expression. To investigate microRNA-mRNA interactions between TS and TV, we performed 
a pairwise correlation taking normalized counts of 
differentially deregulated microRNAs and genes from TS vs. TV comparison. Our analysis 
revealed both positive and negative interactions and full results from this analysis is 
summarized in Supplementary Table 8. Interestingly, we found a subset of microRNAs from 
microRNA module 2 that show negative correlations (Fig 6E) in expression with hub genes 
from RNA module 2 module, the gene cluster that is linked to stress responses and autophagy 
(Fig 5F). Next, we asked whether the expression of this subset of microRNAs from microRNA 
module 2 could be under epigenetic regulation. Therefore, we retrieved their promoters and 
limited our analysis to those microRNAs whose expression is dependent on the host gene 
promoter. Mapping of H3K4me3 peaks on the promoter of these host genes revealed that 
reduction in the expression of this subset of microRNAs in TV was due to reduced H3K4me3 
levels at promoters, at least in part, of their host genes (Fig S6E). These data, coupled with 
observation of TS mice, demonstrate that microRNAs may contribute to cognitive 
improvement by silencing stress-responsive genes. 
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Fig 6. microRNA may reduce the 
expression of ER responsive genes 
A) Scheme of sample preparation and 
sequencing for genome-wide 
microRNA analysis. B) Scheme of co-
expression analysis using all 
expressed microRNAs from all 
experimental groups (n, WV:9, TV:7, 
TS:9) C-D) Two significantly 
deregulated clusters namely 
microRNA module 1 (C) and 
microRNA module 2 (D) are shown. 
Kruskal Wallis test. **p < 0.01. Box 
plot center, lower and upper hinges 
represent the median, first and third 
quartiles respectively E) Heatmap 
summarizes significant negative 
correlation (FDR < 0.05) as observed 
between microRNA members in 
microRNA module 2 and hub genes 
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Discussion 
 
Evidence emerging from recent functional imaging data show that hypoperfusion due to 
chronic heart failure results in tissue loss of different brain regions including hippocampus8, 
the region that is inherently linked with spatial navigation, learning, and memory. However, 
how the brain is functionally affected at the molecular level due to the hypoperfusion remains 
poorly underexplored. To investigate this, in this study, we combined comprehensive systems 
biology using high throughput sequencing data and cognitive phenotyping along with in vitro 
as well as in vivo experiments.  
 
Using a heart failure (HF) mouse model, we demonstrate that reduced cardiac function can 
contribute to substantial changes in hippocampal gene expressions. Our data show that 
increased expression of genes is related to stress response processes, including endoplasmic 
reticulum (ER) stress and autophagy.  On other hand, down-regulated genes are likely to be 
involved in cognition and protein folding. In line with our data, recent study using single-cell 
RNA-seq data from Alzheimer´s disease (AD)  demonstrated that similar processes could be 
altered in early AD pathology73. Moreover, ER stress has been linked with different 
neurodegenerative diseases41. Concordantly our comparative analysis showed that 
transcriptomic changes due to heart failure share similar profile to that from other diseases 
where memory is substantially impaired (e.g., aging, AD, Frontotemporal dementia (FTLD) 
and Parkinson´s disease (PD). Therefore, cardiac failure mice manifest conserved molecular 
changes associated with memory disorders. Thus, heart failure mice could be an excellent 
model to investigate brain´s early molecular changes in the context of dementia. Since 
hypoperfusion precedes major brain structural changes and cognitive deficits, early molecular 
changes owing to hypoperfusion may be used as markers for early diagnosis and to evaluate 
the risk of dementia. 
 
Our HF transgenic mice with reduced ejection fraction displayed both spatial learning and 
memory deficits (Fig 2) at an early age. This finding corroborates with a study on congestive 
cardiac failure model mice74, which exhibited memory deficits in the water maze. However, 
the previous study74 modeled myocardial infarction by ligation of left coronary artery and thus 
represent post-surgical sudden onset of heart failure. Nevertheless, both results confirm the 
association of cardiac failure with memory deficits. In agreement with this, the population-
based Rotterdam study on human HF patients showed that diastolic dysfunction in the heart 
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was associated with an increased risk of dementia75. Two other parallel studies found similar 
results and reported a 1.8-2.1 fold increased risk of all dementia in HF patients76,77.  
Consistently, global cognitive decline affecting different domains including executive 
function, attention, episodic memory, learning and working memory has been reported in 
human HF patients78,79. However, detection of early cognitive changes in humans remains a 
challenge with currently available neuropsychological tests80-82. This could be partly explained 
by the fact that general cognitive tests to evaluate cognitive performance in human does not 
involve spatial orientation and navigation strategies. Recent evidence revealing that spatial 
deficits have higher specificity over other cognitive measures83 and have potential to determine 
early cognitive changes82.  Newly developed virtual reality testing is showing promise of being 
easily applicable in clinical settings and more sensitive in identifying early spatial navigation 
deficits in human84,85. Furthermore, both human real-life version and computerized version of 
Morris water maze was able to find early topographical disorientations in patients86,87. Given 
that spatial navigation deficits is not observed in healthy older individuals88, this may allow 
earlier diagnosis of age-independent cognitive decline in HF patients. Moreover, analysis of 
spatial performance in human HF patients will allow better translation of our mouse HF data 
from the present study to humans.  
 
Based on our comparative analysis, we hypothesized that cognitive deficits in HF mice could 
be attributed to the reduced level of Kmt2a, H3K4 methyltransferase. This reasoning was based 
on previous observations that mice with reduced level of Kmt2a displayed deficits in spatial 
memory and long-term potentiation46,49,89. We previously linked H3K4me3 as a reliable 
indicator of the functionality of Kmt2a46. In consistent to this, we observed a global decline of 
H3K4me3 at promoter of cognition related genes in HF mice. Reduction of H3K4me3 was 
previously observed with reduced a level of Kmt2a46,90. Since H3K4me3 has been linked with 
maintenance of memory90,91, thereby, decreased level of H3K4me3 leading to downregulation 
of cognition related genes may underpin cognitive deficits in HF mice. Interestingly, 
expression of stress-responsive genes was up-regulated despite the reduction of H3K4me3 
level at their promoters. This may be due to their expression being regulated through non-
histone transcription factors or other histone modifications. Moreover, the disparity may come 
from the fact that we performed H3K4me3 from neurons, whereas these genes represent mixed 
cell types (Fig 1).  
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Fig 7. SAHA mediated cognitive rescue in mice following heart failure. 
Heart failure (HF) is characterized by reduced blood flow (hypoperfusion) that can lead to limited nutrient and 
oxygen supply to the brain. Nutrient deprivation and hypoxia are likely to positively influence endoplasmic 
reticulum (ER) stress in the brain. Increased ER stress, in turn, may induce epigenetic and transcriptomic changes 
in the brain, including downregulation of memory-related genes. This study points out of the reduced level of 
H3K4me3 as an underlying molecular mechanism for the down-regulation of memory-related genes following 
hypoperfusion. We report increased protein misfolding in the HF brain that can be attributed to the increased ER 
stress response. Collectively, these molecular changes can contribute to cognitive deficits after HF. Vorinostat 
(SAHA), an inhibitor of histone deacetylase (HDAC), can restore aberrant gene expression changes for the 
memory-related genes and thereby exerts  positive benefits to cognition. Moreover, SAHA can partly restitute 




Available drugs that improve cardiac failure pathology have a limited effect on cognitive 
pathology and dementia risk in HF patients15,16,19-21.  Based on our observation that HF leads 
to brain-related epigenetic changes of gene expression that resemble changes seen in 
neurodegenerative diseases, we tested an epigenetic drug. Vorinostat (SAHA) is an FDA 
approved drug that acts as an inhibitor of histone deacetylase and thereby promotes gene 
expression by opening the chromatin structure. Its efficacy is currently being tested in human 
clinical trial for dementia (ClinicalTrials.gov Identifier: NCT03056495). We report that 
hippocampal-dependent spatial learning and memory as observed in mice with failing heart 
could be rescued with 4 weeks long oral administration of SAHA. Our findings are in line with 
previous study showing oral treatment of SAHA could ameliorate cognitive deficits in aged 
and Alzheimer´s mouse model42. Moreover, the same study reported no detrimental effect of 
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SAHA on peripheral organs42 and others have shown that it can cross blood-brain barrier60,62. 
Consistently, we failed to note significant changes in cardiac phenotype, particularly cardiac 
hypertrophy, after SAHA treatment. Interestingly, this finding is in sharp contrast to a previous 
study92 showing that TSA, another HDAC inhibitor, could ameliorate cardiac hypertrophy. 
However, in support of our observation, another study found no effect of SAHA on heart 
function93. Therefore, the functional impact of different HDAC inhibitors on the heart may 
vary.  
 
Our results show that SAHA could partially restore the hippocampal transcriptomic profile in 
HF mice and that was reflected in the reinstatement of biological processes as well (Fig 7). 
Interestingly, SAHA specifically increased the expression of a cognition related gene 
expression cluster. Hub genes of this cluster include Zeb2, Plppr4, Sema3e, Dock9, CYFIP1, 
GABRb3, Grin2a, Trpc4, Gabra5, Iqgap2, Matn2, Mc4r, Dock4, Scn3b, Pcdh20, Tim2, Slitrk3, 
Chrna7, Itga8, Cacnb2, Itga4; all of which have all been previously linked to synaptic plasticity, 
axonal outgrowth, neuronal activity, dendritic development and memory94-114. Additionally, 
previous studies showed that mice with reduced expression of GABRb399, Gabra5102, 
Trpc4101,115 CYFIP1115, Chrna7111,116 genes developed memory deficits while Mc4r105 gene 
activation rescued cognitive deficits. Therefore, by suppressing the expression of these critical 
genes, cardiac failure induced hypoperfusion may contribute to cognitive decline. In contrast, 
SAHA´s potential to increase their expression make it an ideal candidate for therapeutic 
interventions to improve memory after heart failure. Moreover, hub genes related to cognition 
also include novel gene sets (Lmo7, Pygo1, Fma13c, Tspan13, Cdk17) that have not yet been 
investigated in the context of learning and memory. Functional experiments on these genes in 
the future may shed more light on pathomechanisms during the cognitive decline in HF. 
Furthermore, we observed partial down-regulation of different stress-responsive genes after 
SAHA treatment.  We reproduced SAHA´s protective role against ER stress in cell culture 
using RNA-seq data and later confirmed it in vivo through qPCR. In line with this, previous 
studies reported SAHA´s positive role in maintenance of ER homeostasis117 and protection 
against stress responses118.  
 
The small RNA-seq data further provided insight into the mechanism by which SAHA could 
lower the expression of stress-related genes. Our in-depth analysis revealed a microRNA 
cluster that was up-regulated in transgenic mice (TV) but normalized following SAHA (TS) 
treatment. miR-122-5p, miR-204-5p, miR-211-5p, miR-221-3p, miR-23a-3p, miR-708-5p are 
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part of this cluster and have previously been associated with endoplasmic stress-responsive 
microRNAs119. Our study also provides a list of microRNAs from this cluster that may be 
important to understand stress responses on microRNAs in great detail (Supplementary Table 
7). We also report a second cluster of microRNAs whose expression was down-regulated in 
TV but fully rescued in TS. We found that a subset of microRNA members from this cluster 
showed negative correlations in expression with stress-responsive hub genes. Moreover, 
decreased expression of subset microRNAs in TV could be explained, at least in part, by 
reduced H3K4me3 level at promoters of their host genes (Fig S6E). Therefore, SAHA 
mediated increased expression of these microRNAs may contribute to down-regulation of hub 
genes related to stress.  In addition to the restoration of transcriptomic profile, SAHA´s 
potential to rescue microRNA homeostasis underpins its effectiveness against cognitive 
deficits in the context of heart failure.  
 
In conclusion, we provide evidence that HF leads to epigenetic changes in the hippocampus 
that can contribute to memory impairment. We suggest that epigenetic drug might be a suitable 
strategy to treat cognitive dysfunction in HF patients and lower their risk of developing 
dementia. While future clinical studies will be needed to test the efficacy of SAHA in humans, 
our study highlights its potential as a pharmacological intervention to ameliorate memory 
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Methods & Materials 
Animals 
CamkIIδc transgenic mice were bred according to a previous study25. 2-3 months of transgenic 
mice and corresponding littermate controls were used in this study.  All animals were housed 
in standard cages on 12h/12h light/dark cycle with food and water ad libitum. Experimental 
protocols were approved by FELASA. Animals were sacrificed by cervical dislocation. 
Hippocampal sub-region CA1, CA3 regions were isolated, snap frozen in liquid nitrogen and 
stored at -80 °C. The hearts were dissected by a cut above the base of the aorta and perfused 
with 0.9% sodium chloride solution until blood free, snap frozen in liquid nitrogen and stored 




The heart function and dimensions were examined by echocardiography using a Vevo 2100 
imaging platform (Visualsonics) with 30MHz transducer (MS-400). The animals were 
anesthetized with isoflurane (1-2%) and M-mode sequences of the beating heart recorded in 
the short-axis and the long axis, respectively. The images were used to determine the left 
ventricular end-diastolic and end-systolic Volumes (area*length*5/6). These parameters were 
used to calculate the ejection fraction as indicator of left ventricular heart function. The 
investigator was blinded to genotype and age. 
 
Histology 
Heart was fixed in 4% paraformaldehyde for 24 hours at 4°C, dehydrated in an ethanol series, 
and embedded in paraffin for sectioning. The 5µm paraffin sections were post-fixed with 
Bouin’s solution (HT10132, Sigma Aldrich) and stained using Masson’s trichrome staining kit 
(Sigma, HT15-1KT) according to the manufacturer’s instructions. Bright field images were 
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Behaviourial tests and data analysis 
Open Field & Barnes Maze 
Open field test was performed according to Bahari-Javan et al120. Briefly, mouse was placed 
gently in the middle quadrant of an open field and let it explore for 5 minutes. The travel 
trajectories were recorded using VideoMot (TSE-Systems). Barnes Maze experiment was 
performed according to Sunyer et al121 with slight modifications. Details are summarized in 
Supplementary File.  
 
RNA isolation and sequencing 
RNA isolation was performed using RNA Clean and Concentrator kit according to 
manufacturer protocol without modifications. Concentration was measured on nanodrop and 
quality of RNA was evaluated. For mRNA sequencing, 500 ng total RNA was used as input to 
prepare cDNA libraries according to Illumina Truseq and 50 bp sequencing reads were run in 
HiSeq 2000. For small RNA sequencing, 100 ng total RNA was used as initial input. Small 
RNA was enriched using size selection from based on gel. cDNA library and sequencing have 
been performed according to manufacturer´s protocol (NEBNext Small RNA library prep set 
for Illumina). Next generation sequencing was performed on HiSeq 2000 platform.  
 
Chromatin immunoprecipitation for H3K4me3 
Chromatin immunoprecipitation was performed according to (Halder et al., 2016) with 0.2 µg 
chromatin and 1µg H3K4me3 (ab8580) antibody. ChIPseq library preparation was performed 
using NEBNext Ultra II DNA library preparation according to manufacturer’s protocol. 2nM 
libraries were pooled and sequenced in Illumina Hiseq 2000 with 50-bp single end reads. 
Details are given in Supplementary File.  
 
Oral administration of SAHA 
SAHA was dissolved in drinking water according to a previous study42. 0.67 g of SAHA 
(Cayman Chemical Co.) was dissolved in 1 l of drinking water containing 18 g of β-
cyclodextrin (Sigma-Aldrich, Ref 332607). The solution was heated at 70°C and mixed on a 
magnetic stirrer until SAHA was fully dissolved and left it overnight to cool down. The next 
day, Animals were given drug mixed water Control groups only received water with β-
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cyclodextrin (18 g/ 1L). The previous study has showed that the given dose in the mouse would 
be equivalent to 375 mg/day in humans which is within the tolerable dose.  
 
Modeling endoplasmic reticulum stress in primary neurons 
Primary neuronal culture was prepared according to Eva benito et al.122 (see Supplementary 
File for details). Experiments were performed at DIV 10. Endoplasmic reticulum stress was 
induced in primary hippocampal neurons using Tunicamycin (Sigma Aldrich). 2ug/mL of 
Tunicamycin was added to primary neuronal culture and incubated for 6 hours and compared 
to those treated with DMSO for same time. For SAHA treatment, 1 µM of vorinostat (SAHA, 
Cayman Chemical Co.) was added to culture 1 hour prior to Tunicamycin treatment. Neurons 
were treated with Trizol and stored at -80°c until RNA isolation. RNA isolation was performed 
as discussed earlier.  
 
Quantitative RT-PCR  
qPCR (q-PCR) primers were designed using Universal probe library Assay Design Center and 
were purchased from Sigma. Transcriptor High Fidelity cDNA Synthesis Kit (Roche) was used 
to prepare cDNA. UPL probes were used for quantification and data was normalized to HPRT1 
expression as internal control. Relative gene expression was analyzed by 2−ddCt method. 
Primer sequences are summarized in Supplementary File. 
 
Western blot  
Chromatin-bound nuclear fractions were extracted from cultured cells using the Subcellular 
Protein Fractionation Kit for Cultured Cells (Thermo-Scientific, 78840). Western blot was 
performed according to previous study120. To quantify H3K4me3 and H3K9ac levels 
H3K4me3 (abcam, ab8580) antibody, H3K9ac (abcam, ab4441) antibody were used 
respectively. Unmodified H3 level measured with H3 antibody (abcam, ab1791) was used as 
internal control. Detailed procedure is summarized in Supplementary File. 
 
Bioinformatics analysis 
Bulk RNA Sequencing data analysis has been performed according to Wendeln et al32. Small 
RNA sequencing files were analyzed according to using miRDeep2. A wrapper of the steps 
applied during mapping and counting is uploaded and available as package 
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(https://github.com/mdrezaulislam/MicroRNA). Differentially expressed genes or microRNAs 
were determined using mixed linear model accounting for technical and biological covariates. 
For linear mixded effects model, limma in R was implemented.  Biological processes were 
analyzed using Gene Ontology (http://geneontology.org/).  For pathway analysis KEGG 
(https://www.genome.jp/kegg/), Reactome (https://reactome.org/) databases were used. Exon 
counts were generated using DEXSeq (http://bioconductor.org/packages/DEXSeq/). 
Hypergeometric test analysis was performed using GeneOverlap 
(http://bioconductor.org/packages/GeneOverlap/). H3K4me3 narrow peaks were called using 
MACS2. Chip peaks were mapped at promoter (TSS ± 2kb) of genes using ngs.plot. Results 
from pairwise correlation between H3K4me3 peaks and RNA expression was visualized using 
EnrichedHeatmap. Weighted co-expression analysis for both microRNAs and mRNAs was 
performed using WGCNA67. External gene expression datasets that have been used from other 
studies were downloaded from NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) and mapped 
in house to have consistency in results. Details of microRNA promoter and host genes and 
other analysis are summarized in Supplementary File.  
 
Statistical analysis 
All the statistical analyses as mentioned in the main text are performed in Prism (version 7.0) 
or in R.  
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Fig S1. RNA-seq data in transgenic mice.   
A-C) Tibia length, lung/body weight ratio, lung weight/tibia length ratio between CamkIIδc transgenic mice (n = 
8) and littermate controls (n = 5). Error bar indicates mean ± sem. D) Heatmap showing deregulated genes in heart 
from human patients with heart failure (n = 5) compared to healthy controls (n = 4). E) Featured biological 
processes for down-regulated genes. X-axis represents -log10 (FDR). F) Expression of neuronal splicing factors 
between control and transgenic mice. Error bar indicates mean ± sem. G) Dot-plot showing top significant 
pathways that the deregulated genes may potentially regulate. The color label indicates the level of significance 







Islam et al. 2019  Research Article 2 
   103 
 
Fig S2. Experimental settings and Different mouse strategies in Barnes Maze.  
A) Barnes maze experimental setup is divided into habituation (mice acclimatize with the experimental 
environment, get exposure to light and sound, perform first experimental task), training trials, and probe test. 
Initial Training trials help mice learning to locate an escape hole. After several training trials, mice could recall 
the location of the escape hole during probe test, albeit escape hole is covered during the test. Figure B illustrating 
different strategic trajectories that mice can employ to locate and then hide in the escape hole, hence the unique 
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Fig S3. SAHA increases the H3K4me3 level in primary neurons.  
A) Western blot for H3K4me3 and H3K9ac after 1hour of SAHA (1 uM) and DMSO treatment in primary 
neurons. Two replicates represent pooled samples (n = 3) from two independent experiments. Experiment was 
done at day in vitro 10.  Relative Intensity was normalized to H3 level. Error bar indicates mean ± sem. B) 
Enrichment analysis of deregulated genes in CamkIIδc transgenic with those of old vehicle (OV), young vehicle 
(YV) and old SAHA (OS) mice. Data are retrieved from Benito et al. 2015. Fold enrichment, significance value, 
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Fig S4. Weighted gene co-expression analysis.  
A) Significantly deregulated genes in TV vs. WV and TS vs. WT groups (FDR < 0.05). Up- and down-regulated 
genes are represented in darkred and darkblue colors respectively B) Venn diagram showing common and 
uniquely deregulated genes between TV vs. WV and TS vs. WV conditions. C) differential exon usage pattern 
(FDR<0.05) in TV vs. WV and TS vs. WV conditions   D) soft power selection based on scale independence and 
mean connectivity for different modules identification in WGCNA.  E) Different modules representing distinct 
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Figure S5. Effect of orally administered SAHA in transgenic mice.  
A) Scheme for SAHA or vehicle treatment in transgenic and littermate controls B-C) Body weight and lung weight 
was similar among groups. D-E) Heart and left ventricular weights increased in both TV and TS groups compared 
to WV. Violin plot includes densities and box plot. White dot represents each mouse´s performance. Kruskal 
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Fig S6. SAHA partially rescues ER stress-related gene expression changes in vitro and in vivo.  
A) Scheme for modeling ER stress using tunicamycin (2ug/ml) and SAHA mediated rescue experiment.  
Experiment was performed on day in vitro 10 of primary neuronal culture from the hippocampus. Heatmap 
showing deregulated genes expression in DMSO, tunicamycin and SAHA pre-treatment + tunicamycin groups. 
Red rectangular box indicating gene sets that deregulated in response to tunicamycin, are restored in SAHA + 
tunicamycin group. B) Featured significant GO biological processes. Response to ER response (highlighted in red 
color) is reduced in SAHA pretreatment group. Dot size represents gene ratio while significance level is 
represented with color. C) qPCR showing mRNA expression pattern of Bcap31 and Fez2 in three groups. Data 
normalized to WT vehicle (WV). (WT vehicle: n=10, TG vehicle: n=9, TG SAHA: n=8; multiple t-test, *p<0.05, 
**p<0.001, error bars indicate mean ± sem). D) Expression of microRNA modules from WGCNA analysis in 
three experimental groups. WV: n = 9; TV: n = 7; TS: n = 10; Kruskal Wallis test. E) H3K4me3 profile at promoter 
of genes that harbor microRNAs. H3K4me3 level at promoter of these genes is significantly reduced in transgenic 
mice. Unpaired t -test, *p<0.05   
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Discussion 
 
Dementia is a slow and progressive neurodegenerative disorder with molecular and metabolic 
changes taking place years before the onset of disease109. With currently available markers and 
cognitive tests, patients are only diagnosed at an advanced stage of memory decline. As a result, 
drugs tested so far to improve cognition in demented subjects have been unsuccessful110-112. 
However, an early diagnostic marker will provide opportunities for therapeutic intervention at 
an earlier stage before substantial neuronal death and brain damage occurs. Moreover, 
understanding of risk factors and their mechanism to affect cognition will pave the way for 
deciphering molecular underpinnings at early dementia. Despite high demand, useful markers 
to diagnose dementia at the pre-clinical stage are still missing. Moreover, the contribution of 
risk factors at an early stage of memory deficits is poorly understood. Therefore, in this 
dissertation, I tested the hypothesis that microRNA-based signatures could be potentially 
informative about early cognitive changes. In a second approach, I investigated the underlying 
molecular mechanism of cognitive decline due to heart failure (HF), a risk factor of dementia, 
and explored whether a therapeutic intervention would be able to restore brain functions in HF 
patients.  
 
In the first study, we identify a blood-based “microRNA signature” consisting of three 
microRNAs (miR-146a-5p, miR-181a-5p, and miR-148-3p) for diagnosis of early cognitive 
decline. Co-expression of this signature showed a robust increased pattern in blood at the early 
onset of cognitive deficits in both healthy mouse and human. Increased co-expression of 
“microRNA signature” was also observed in the aging brain and that of 4 months old APP/PS1 
mice, an Alzheimer's disease (AD) mouse model. Of note, at four months of age, APP/PS1 mice 
show no overt memory impairment (Agbemenyah et al., unpublished). Interestingly, human 
MCI patients displayed increased co-expression of this signature compared to age-matched 
controls. This increment in expression was not limited to human blood but also observed in 
human cerebrospinal fluid (CSF). In line with these data, we observed increased expression of 
“microRNA signature” in the brains of various mouse models for memory impairment and AD. 
This is very interesting, since it indicated that changes in ““microRNA signature” could inform 
about relevant pathomechanisms in the CNS. Indeed, when I injected inhibitors of a selected 
microRNA into the hippocampus of mice suffering from memory impairment, this phenotype 
was reversed.  In summary, our study demonstrates that co-expression of “microRNA 
signature” in the blood can be sensitive to detect early dementia. 
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 Although previous studies reported microRNAs-based biomarkers for dementia113-119, our 
“microRNA signature” is different for several reasons. First, previously reported biomarkers 
were discovered by cross-sectional comparison between healthy and disease conditions and 
therefore, do not reflect a progressive decline in memory performance113-116,118,119. Second, 
those biomarkers showed high variability in expression depending on its source120,121. Third, 
studies reporting those biomarkers showed conflicting results and were often based on low-
quality sequencing data and fewer sample numbers. By contrast, that approach that I adapted is 
based on the integrative analysis of healthy humans, longitudinal monitoring of changes in 
cognitive performance in mice, patients, and disease models. Therefore, our signature appears 
more robust for the early detection of incipient dementia. Consistently, our signature shows 
similar distinct expression changes across various body fluid sources. Since similar results were 
observed across several datasets from mouse and human, the “microRNA signature” likely 
reflects a conserved early pathomechanism in dementia between mice and humans. However, 
questions remain whether this signature will be able to predict the onset of future dementia. 
Together with a large longitudinal cohort having well-characterized cognitive information and 
application of deep learning models on sequencing data, future studies will be able to 
investigate this.  
 
How can this signature be informative about early cognitive changes? To find an answer, we 
investigated a recent genome-wide association study (GWAS) and retrieved genes that have 
been associated with general cognition122. Interestingly, target genes of all three microRNAs 
from our signature significantly overlap with those genes. These data imply that by interacting 
with crucial memory-related genes, microRNA members of “microRNA signature” may 
influence learning and memory. Consistently, by modulating one microRNA from signature, 
miR-181a-5p, we have shown its causal link with memory deficits. However, this result is in 
sharp contrast to two recent studies showing that miR-181a-5p is important for memory 
formation123,124. This discrepancy could be due to the fact that those two studies investigated 
contextual fear memory whereas we tested spatial navigation in mice. Unlike fear memories 
that can be formed without the involvement of the hippocampus, spatial navigation is solely 
dependent on it125. Therefore, the modulation of microRNA in the dorsal hippocampus might 
have limited influence in fear memory formation. Moreover, using cell culture model, we found 
that increased expression of microRNA-181a-5p leads to the down-regulation of cognition 
related genes, and they are conserved in various neurodegenerative diseases. Therefore, its 
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increased expression is likely to be a detriment to cognition as we have observed. Further 
confidence on this stem from selective inhibition of miR-181a-5p in the dorsal hippocampus. 
We observed that inhibition of miR-181a-5p could ameliorate cognitive deficits in old mice. 
Will inhibition of all three microRNAs improve memory as well? Can this inhibition restore 
memory in Alzheimer's disease? Our preliminary results from mice study demonstrate that 
inhibition of our signature (all three microRNAs) can ameliorate cognitive deficits in old and 
APP/PS1 (Alzheimer's mouse model) mice. However, questions remain about its plausible 
mechanism. Future experiments will address this using high throughput sequencing and 
imaging technologies. 
  
What can trigger the expression changes of the “microRNA signature”? We reasoned that 
different risk factors might play a role. To test this conjecture, in the second part of the 
dissertation, we investigated the role of heart failure (HF) as a risk factor to modulate brain 
functions. By using a cardiac failure mouse model, we could show that hypoperfusion from 
heart failure can lead to dramatic gene expression changes in the hippocampus. This alteration 
in gene expression profile overlapped with that from hypoxic or increased stress condition. 
Moreover, the changes are in line with findings from a recent study based on single cell RNS-
seq data from early Alzheimer´s disease (AD)126. Furthermore, gene expression changes were 
highly conserved with various neurological diseases. Consistently, HF mice exhibited deficits 
in both the acquisition and recovery of memory in a spatial learning task. Observed memory 
deficits were also reported in a previous study after myocardial infarction127. By analyzing the 
distribution of H3K4me3, a histone modification, at the promoter of genes, we could show that 
a causal relationship exists between H3K4me3 level and reduced expression of cognition 
related genes. H3K4me3 is essential for maintenance of memory81,128, therefore, a decreased 
level of H3K4me3 may underpin observed cognitive deficits. Growing evidence suggests that 
human heart failure patients also exhibit memory decline129-133. Given that targeted therapy to 
improve memory in human HF patients is missing134-137, we tested SAHA´s potential as 
therapeutic intervention. Oral administration of SAHA increased both cognition related gene 
expression and cognitive performance in HF mice. Our findings are in line with a previous 
study showing oral treatment of SAHA provides cognitive benefits to aged and Alzheimer´s 
mouse model79 
 
SAHA could normalize microRNA expression changes in HF mice. Intriguingly, when the 
expression of the “microRNA signature” from the first part of the dissertation was investigated 
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in the HF model, we found an increased expression of the signature in HF mice (Fig T8). This 
result provides further evidence that the “microRNA signature” could be used as a marker for 
the diagnosis of early cognitive decline and therapeutic efficacy. These data further imply that 
hypoperfusion may trigger the changes in expression change of “microRNA signature”. 
Additionally, SAHA could restore expression changes of this “microRNA signature”. This data 
supports our previous experimental results that reduced expression of “microRNA signature” 





Fig T8. Co-expression analysis of “microRNA signature” in 
the HF model. Transgenic mice (CamKIIẟc) were given 
SAHA in drinking water for four weeks. Littermate controls 
and additional transgenic mice groups received drinking water 
with sugar (vehicle) only. The “microRNA signature” shows 
increased expression in transgenic vehicle group compared 
with wild type vehicle. However, Transgenic mice with SAHA 
treatment show reinstatement in “microRNA signature” 
expression. n, wild type vehicle:9, transgenic vehicle: 7, 
transgenic SAHA: 9; Kruskal-Wallis test. Box plot center, 
lower and upper hinges represent the median, first, and third 
quartiles, respectively.  
 
 
In conclusion, the first study reveals potentials of “microRNA signature” as a diagnostic marker 
for early dementia, and the second study explores pathomechanism of early cognitive deficits 
due to cardiovascular risk factor and demonstrates the efficacy of SAHA in the cognitive 
improvement of HF subjects. While future clinical applications for the “microRNA signature” 
in early risk diagnosis of dementia and SAHA based improved cognition for heart failure 
patients remain to be tested, these two studies provide critical insights about the marker, 
molecular underpinnings, and therapy of early cognitive deficits. Further questions remain 
regarding whether hypoperfusion could be an additional biomarker for accurate detection of 
early dementia, how the management of cardiovascular risk factors would influence brain 
function and whether lifestyle and exercise could be a preventive measure for early onset of 
dementia. 
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